0001493152-19-012287.txt : 20190814 0001493152-19-012287.hdr.sgml : 20190814 20190814060810 ACCESSION NUMBER: 0001493152-19-012287 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190814 DATE AS OF CHANGE: 20190814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sintx Technologies, Inc. CENTRAL INDEX KEY: 0001269026 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33624 FILM NUMBER: 191022670 BUSINESS ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 BUSINESS PHONE: 801-839-3516 MAIL ADDRESS: STREET 1: 1885 WEST 2100 STREET CITY: SALT LAKE CITY STATE: UT ZIP: 84119 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA Corp DATE OF NAME CHANGE: 20121231 FORMER COMPANY: FORMER CONFORMED NAME: AMEDICA CORP DATE OF NAME CHANGE: 20031104 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-33624

SINTX Technologies, Inc.

(previously known as “Amedica Corporation”)

(Exact name of registrant as specified in its charter)

DELAWARE		84-1375299
(State or other jurisdiction		(IRS Employer
of incorporation or organization)		Identification No.)

1885 West 2100 South, Salt Lake City, UT		84119
(Address of principal executive offices)		(Zip Code)

(801) 839-3500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock		SINT		The NASDAQ Capital Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days: Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files); Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]

		Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

1,957,930 shares of common stock, $0.01 par value, were outstanding at August 12, 2019.

SINTX Technologies, Inc.

(previously known as Amedica Corporation)

Table of Contents

Part I. Financial Information
Item 1. Financial Statements
Condensed Consolidated Balance Sheets (unaudited)	3
Condensed Consolidated Statements of Operations (unaudited)	4
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)	5
Condensed Consolidated Statements of Cash Flows (unaudited)	6
Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3. Quantitative and Qualitative Disclosures About Market Risk	26
Item 4. Controls and Procedures	26
Part II. Other Information
Item 1. Legal Proceedings	27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3. Defaults Upon Senior Securities	27
Item 4. Mine Safety Disclosures	27
Item 5. Other Information	27
Item 6. Exhibits	28
Signatures	29

SINTX Technologies, Inc.

(previously known as Amedica Corporation)

Condensed Consolidated Balance Sheets - Unaudited

(in thousands, except share and per share data)

	June 30, 2019			December 31, 2018

Assets
Current assets:
Cash and cash equivalents	$	3,192		$	5,447
Trade accounts receivable, net of allowance of $6 and $56, respectively		173			263
Prepaid expenses and other current assets		234			171
Inventories		85			52
Notes receivable, current portion		1,399			1,084
Total current assets		5,083			7,017

Inventories, net		596			624
Property and equipment, net		87			124
Intangible assets, net		44			46
Long-term note receivable, net of current portion		2,897			3,669
Operating lease right-of-use-asset		2,535			-
Other long-term assets		35			35
Total assets	$	11,277		$	11,515

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	295		$	301
Accrued liabilities		813			838
Derivative liabilities, current portion		454			1,062
Current portion of operating lease liability		587			169
Other current liabilities		23			10
Total current liabilities		2,172			2,380

Operating lease liability, net of current portion		2,050			-
Derivative liabilities, net of current portion		502			504
Other long-term liabilities		113			232
Total liabilities		4,837			3,116

Commitments and contingencies		-			-

Stockholders’ equity:
Convertible preferred stock, $0.01 par value, 130,000,000 shares authorized; 737 shares and 4,074 shares issued and outstanding at June 30, 2019 and December 31, 2018.		-			-
Common stock, $0.01 par value, 250,000,000 shares authorized; 1,854,898 shares, and 726,455 shares issued and outstanding at June 30, 2019 and December 31, 2018.		19			7
Additional paid-in capital		238,062			237,673
Accumulated deficit		(231,641	)		(229,281	)
Total stockholders’ equity		6,440			8,399
Total liabilities and stockholders’ equity	$	11,277		$	11,515

The condensed consolidated balance sheet as of December 31, 2018, has been prepared using information from the audited consolidated balance sheet as of that date.

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

(previously known as Amedica Corporation)

Condensed Consolidated Statements of Operations - Unaudited

(in thousands, except share and per share data)

	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Product revenue	$	167		$	-		$	264		$	-
Costs of revenue		133			-			212			-
Gross profit		34			-			52			-
Operating expenses:
Research and development		836			956			1,554			1,833
General and administrative		615			935			1,586			2,242
Sales and marketing		105			11			164			58
Total operating expenses		1,556			1,902			3,304			4,133
Loss from operations		(1,522	)		(1,902	)		(3,252	)		(4,133	)
Other income (expenses):
Interest expense		(2	)		(809	)		(2	)		(1,284	)
Interest income		115			-			237			-
Change in fair value of derivative liabilities		631			1,209			610			2,020
Loss on extinguishment of debt		-			-			-			(340	)
Offering costs		-			(682	)		-			(682	)
Loss on extinguishment of derivative liabilities		-			-			-			(1,252	)
Other income, net		48			3			48			5
Total other income (expense), net		792			(279	)		893			(1,533	)
Net loss from continuing operations before income taxes		(730	)		(2,181	)		(2,359	)		(5,666	)
Provision for income taxes		-			-			-			-
Loss from continuing operations		(730	)		(2,181	)		(2,359	)		(5,666	)
Loss from discontinued operations		-			(131	)		-			(44	)
Net loss	$	(730	)	$	(2,312	)	$	(2,359	)	$	(5,710	)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock		(2,358	)		(7,334	)		(2,358	)		(7,334	)
Net loss attributable to common stockholders	$	(3,088	)	$	(9,646	)	$	(4,717	)	$	(13,044	)
Net loss per share – basic and diluted
Basic – continuing operations	$	(0.78	)	$	(11.19	)	$	(2.84	)	$	(36.66	)
Basic – discontinued operations		-			(0.67	)		-			(0.28	)
Basic - deemed dividend and accretion of a discount on conversion of series B preferred stock		(2.53	)		(37.62	)		(2.84	)		(47.46	)
Basic – attributable to common stockholders	$	(3.31	)	$	(49.48	)	$	(5.68	)	$	(84.40	)

Diluted – continuing operations	$	(1.46	)	$	(12.06	)	$	(3.58	)	$	(39.01	)
Diluted – discontinued operations		-			(0.42	)		-			(0.28	)
Diluted - deemed dividend and accretion of a discount on conversion of series B preferred stock		(2.53	)		(23.33	)		(2.84	)		(47.46	)
Diluted – attributable to common stockholders	$	(3.99	)	$	(35.81	)	$	(6.42	)	$	(86.75	)
Weighted average common shares outstanding:
Basic		931,859			194,933			829,724			154,545
Diluted		931,859			314,354			829,724			154,545

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

(previously known as Amedica Corporation)

Condensed Consolidated Statements of Stockholders’ Equity - Unaudited

(in thousands, except share and per share data)

	Preferred Stock					Common Stock				Paid-In			Accumulated			Total
	Shares			Amount		Shares		Amount		Capital			Deficit			Equity
Balance at December 31, 2017		-		$	-		100,935	$	1	$	226,070		$	(220,629	)	$	5,442
Common stock issued from exercise of warrants		-			-		27,139		-		1,633			-			1,633
Issuance of common stock in exchange for reduction in debt		-			-		19,348		-		1,453			-			1,453
Issuance of preferred stock from offering, net of issuance costs		15			-		-		-		6,754			-			6,754
Warrants issued in association with debt		-			-		-		-		98			-			98
Loss on extinguishment of derivative liabilities		-			-		-		-		1,040			-			1,040
Deemed dividend related to adjustment of the exercise price of warrants issued with debt		-			-		-		-		(9	)		-			(9	)
Accretion of change in warrant exercise price		-			-		-		-		9			-			9
Common stock issued due to conversion of preferred stock		(4	)		-		102,886		1		(1	)		-			-
Accretion of convertible preferred stock discount		-			-		-		-		7,334			-			7,334
Deemed dividend related to the issuance of preferred stock		-			-		-		-		(7,334	)		-			(7,334	)
Extinguishment of derivative liabilities		-			-		-		-		565			-			565
Stock-based compensation		-			-		-		-		34			-			34
Net loss		-			-		-		-		-			(5,710	)		(5,710	)
Balance at June 30, 2018		11		$	-		250,308	$	2	$	237,646		$	(226,339	)	$	11,309

	Preferred Stock					Common Stock				Paid-In			Accumulated			Total
	Shares			Amount		Shares		Amount		Capital			Deficit			Equity
Balance at December 31, 2018		4,074		$	-		726,455	$	7	$	237,673		$	(229,281	)	$	8,399
Common stock issued from exercise of warrants		-			-		500		-		1			-			1
Common stock issued due to conversion of preferred stock		(3,337	)		-		983,528		10		(10	)		-			-
Stock based compensation		-			-		-		-		1			-			1
Common stock issued for cash		-			-		144,415		1		396						397
Removal of derivative liability upon exercise of warrant		-			-		-		-		1			-			1
Net loss		-			-		-		-		-			(2,359	)		(2,359	)
Balance at June 30, 2019		737		$	-		1,854,898	$	18	$	238,062		$	(231,640	)	$	6,440

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX Technologies, Inc.

(previously known as Amedica Corporation)

Condensed Consolidated Statements of Cash Flows - Unaudited

(in thousands)

	Six Months Ended June 30,
	2019			2018
Cash flow from operating activities
Net loss from continuing operations	$	(2,359	)	$	(5,666	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		52			53
Non-cash lease expense		171			(99	)
Amortization of intangible assets		2			-
Amortization of lease incentive for tenant improvements		-			28
Non-cash interest income		(237	)		-
Non-cash interest expense		-			812
Loss on extinguishment of debt		-			340
Stock based compensation		1			34
Change in fair value of derivative liabilities		(610	)		(2,020	)
Loss on extinguishment of derivative liabilities		-			1,252
Loss on disposal of equipment		-			51
Bad debt expense		9			-
Changes in operating assets and liabilities:
Trade accounts receivable		79			-
Prepaid expenses and other current assets		(63	)		(76	)
Inventories		(5	)		-
Accounts payable and accrued liabilities		(19	)		(241	)
Net cash used in operating activities - continuing operations		(2,979	)		(5,532	)
Net cash used in operating activities - discontinued operations		-			(402	)
Net cash used in operating activities		(2,979	)		(5,934	)
Cash flows from investing activities
Purchase of property and equipment		(15	)		-
Proceeds from notes receivable, net of imputed interest		695			-
Purchase of intangible asset		-			(50	)
Net cash provided by (used in) investing activities – continuing operations		680			(50	)
Net cash used in investing activities – discontinued operations					(107	)
Net cash used in investing activities		680			(157	)
Cash flows from financing activities
Proceeds from issuance of stock in connection with exercise of warrants, net of issuance costs		1			1,633
Proceeds from issuance of common stock, net of fees ($131)		397			-
Proceeds from issuance of preferred stock, net of issuance costs ($668)		-			6,754
Proceeds from issuance of warrant derivative liabilities, net of issuance costs ($682)		-			7,577
Payments on operating lease liability		(354	)		-
Proceeds from issuance of debt		-			705
Payments on debt		-			(2,282	)
Net cash provided by (used in) financing activities		44			14,387
Net increase (decrease) in cash and cash equivalents		(2,255	)		8,296
Cash and cash equivalents at beginning of period		5,447			539
Cash and cash equivalents at end of period	$	3,192		$	8,835

Noncash investing and financing activities
Right-of-use assets and assumption of operating lease liability	$	2,704		$	-
Reduction of derivative liability due to exercise of warrants		1			-
Hercules and MEF I, LP/Anson Investments Debt Exchange		-			2,265
Issuance of common stock in exchange for reduction in debt		-			1,453
Extinguishment of derivative liabilities through exercise of warrants		-			565
Warrants issued in association with debt		-			98
Supplemental cash flow information
Cash paid for interest	$	2		$	337

The accompanying notes are an integral part of these condensed consolidated financial statements.

SINTX TECHNOLOGIES, INC.

(PREVIOUSLY KNOWN AS AMEDICA CORPORATION)

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Organization and Summary of Significant Accounting Policies

Organization

SINTX Technologies, Inc. (“SINTX” or “the Company”) (previously known as Amedica Corporation) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Company’s products are primarily sold in the United States.

As further explained in Note 12, On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical, a Dallas, Texas-based privately held medical device manufacturer. As a result of the sale, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.

On October 30, 2018, the Company amended its Certificate of Incorporation with the State of Delaware to change its corporate name to SINTX Technologies, Inc. in order to better reflect its focus on silicon nitride science and technologies and pipeline of silicon nitride-based products in various biomedical applications. The Company also changed its trading symbol on the NASDAQ Capital Market to “SINT”. The Company also changed the name of its wholly owned subsidiary US Spine, Inc. to “ST Sub, Inc.”

The previous name, Amedica, has transferred to CTL Medical, which is now CTL-Amedica. The Company’s new corporate brand reflects both the Company’s core competence in the science and production of silicon nitride ceramics, as well as encouraging prospects for the future, as an OEM supplier of spine implants to CTL-Amedica, and several opportunities outside of spine. The Company will focus on developing silicon nitride in terms of product design, and future biomaterial formulations, for a variety of OEM customers.

As further explained in Note 14, the Company effected a 1 for 30 reverse stock split of the Company’s common stock on July 26, 2019.

Basis of Presentation

These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company and its wholly owned subsidiary, ST Sub, Inc. All material intercompany transactions and balances have been eliminated in consolidation. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 11, 2019. The results of operations for the six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2018.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the periods then ended. Actual results could differ from those estimates. The most significant estimates relate to inventory, long-lived and intangible assets and the liability for preferred stock and common stock warrants.

Liquidity and Capital Resources

The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.

For the six months ended June 30, 2019 and 2018, the Company incurred net losses from continuing operations of approximately $2.4 million and $5.7 million, respectively, and used cash in continuing operations of approximately $3.0 million and $5.5 million, respectively. The Company had an accumulated deficit of approximately $232 million and $229 million as of June 30, 2019 and December 31, 2018, respectively. To date, the Company’s operations have been principally financed by proceeds received from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operating activities. The Company’s continuation as a going concern is dependent upon its ability to increase sales and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operating activities or obtain additional financing is uncertain.

The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of the Company’s silicon nitride material are not well known, and the Company believes that the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.

The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering. In March 2018, the Company closed on gross proceeds of $1.4 million, before payment of placement agent fees and costs on a warrant reprice and exercise transaction. Additionally, on May 14, 2018, the Company closed on a public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of our common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $1.6 million, (ii) the termination by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) June 4, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the three months ended June 30, 2019 the Company raised $0.397 million, net of fees through the issuance of 144,415 shares of common stock under the Distribution Agreement with Maxim. The Company is eligible to raise an additional $1.2 million under this offering. In addition, the Company converted 3,337 shares of preferred stock into 983,528 shares of common stock. The Company is engaged in discussions with investment and banking firms to examine financing alternatives, including options for a public offering of the Company’s preferred or common stock. On October 1, 2018, the Company sold the retail spine business. This sale will continue to provide cash flows from July 2019 totaling $1.4 million over the next ten months and $3.5 million for the following eighteen months. The buyer also assumed the Company’s $2.5 million related party note payable.

Although the Company is seeking to obtain additional equity and/or debt financing, such funding is not assured and may not be available to the Company on favorable or acceptable terms and may involve significant restrictive covenants. Any additional equity financing is also not assured and, if available to the Company, will most likely be dilutive to its current stockholders. If the Company is not able to obtain additional debt or equity financing on a timely basis, the impact on the Company will be material and adverse.

These uncertainties create substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Significant Accounting Policies

Except as explained below, no material changes were made to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Accounting Pronouncements Adopted During the Quarter Ended June 30, 2019

In August 2016, the FASB updated accounting guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Under prior U.S. GAAP, there was no specific guidance on the eight cash flow classification issues aforementioned. The Company adopted the new guidance effective January 1, 2019. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption.

In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The Company adopted the new guidance effective January 1, 2019 (see Note 13), using the modified retrospective approach. Adoption of the new guidance resulted in the Company being required to record an additional operating lease right-of-use asset totaling approximately $0.659 million and liability totaling approximately $0.946 million (with $0.659 million incremental to adoption of the new guidance) on the date of adoption. Subsequent to the initial adoption of the new standard the Company amended the lease (see Note 13). The standard did not materially impact the consolidated net loss and had no impact on cash flows.

In May 2014, in addition to several amendments issued during 2016, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The Company adopted the new guidance effective January 1, 2019. The core principle of the new guidance is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates are often required within the revenue recognition process than were required under prior U.S. GAAP. The Company has one primary customer (see Note 12) and related contract that has one performance obligation to which revenue is allocated. Revenue under this contract is recognized when the product is shipped to the customer. The Company generally bills its customer upon shipment of the product and invoices are generally due within 30 days. The Company does provide certain rights of return, which historically have not been significant. The Company does not anticipate incurring significant incremental costs to obtain contracts with future customers. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption.

New Accounting Pronouncements Not Yet Adopted

The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

2. Basic and Diluted Net Loss per Common Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock, warrants for the purchase of common stock and stock options. The Company had potentially dilutive securities, totaling approximately 0.6 million and 0.7 million as of June 30, 2019 and 2018, respectively.

Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(730	)	$	(632	)	$	(1,362	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(3,088	)	$	(632	)	$	(3,720	)

Denominator:
Number of shares used in per common share calculations:		931,859			-			931,859

Net loss per common share:
Loss from continuing operations	$	(0.78	)	$	-		$	(1.46	)
Deemed dividend and accretion of a discount		(2.53	)		-			(2.53	)
Net loss attributable to common stockholders	$	(3.31	)	$	-		$	(3.99	)

Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(2,359	)	$	(609	)	$	(2,968	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(4,717	)	$	(609	)	$	(5,326	)

Denominator:
Number of shares used in per common share calculations:		829,724			-			829,724

Net loss per common share:
Loss from continuing operations	$	(2.84	)	$	-		$	(3.58	)
Deemed dividend and accretion of a discount		(2.84	)		-			(2.84	)
Net loss attributable to common stockholders	$	(5.68	)	$	-		$	(6.42	)

Below are basic and diluted loss per share data for the three months ended June 30, 2018, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(2,181	)	$	(1,610	)	$	(3,791	)
Income from discontinued operations		(131	)		-			(131	)
Deemed dividend and accretion of a discount		(7,334	)		-			(7,334	)
Net loss attributable to common stockholders	$	(9,646	)	$	(1,610	)	$	(11,256	)

Denominator:
Number of shares used in per common share calculations:		194,933			119,421			314,354

Net loss per common share:
Loss from continuing operations	$	(11.19	)	$	-		$	(12.06	)
Loss from discontinued operations		(0.67	)		-			(0.42	)
Deemed dividend and accretion of a discount		(37.62	)		-			(23.33	)
Net loss attributable to common stockholders	$	(49.48	)	$	-		$	(35.81	)

Below are basic and diluted loss per share data for the six months ended June 30, 2018, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(5,666	)	$	(362	)	$	(6,028	)
Income from discontinued operations		(44	)		-			(44	)
Deemed dividend and accretion of a discount		(7,334	)		-			(7,334	)
Net loss attributable to common stockholders	$	(13,044	)	$	(362	)	$	(13,406	)

Denominator:
Number of shares used in per common share calculations:		154,545			-			154,545

Net loss per common share:
Loss from continuing operations	$	(36.66	)	$	-		$	(39.01	)
Loss from discontinued operations		(0.28	)		-			(0.28	)
Deemed dividend and accretion of a discount		(47.46	)		-			(47.46	)
Net loss attributable to common stockholders	$	(84.40	)	$	-		$	(86.75	)

3. Inventories

Inventories consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Raw materials	$	596	$	624
Intermediate goods		9		-
WIP		76		47
Finished goods		-		5
	$	681	$	676

As of June 30, 2019, inventories totaling approximately $0.08 million and $0.6 million were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of June 30, 2019, that management estimates will be sold by June 30, 2020.

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Trademarks	$	50		$	50
Less: accumulated amortization		(6	)		(4	)
	$	44		$	46

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:

	Level 1 -	quoted market prices for identical assets or liabilities in active markets.

	Level 2 -	observable prices that are based on inputs not quoted on active markets but corroborated by market data.

	Level 3 -	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of June 30, 2019 and December 31, 2018. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2019 and December 31, 2018:

	Fair Value Measurements as of June 30, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	956	$	956

	Fair Value Measurements as of December 31, 2018
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,566	$	1,566

The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended June 30, 2019 and 2018.

	Common Stock Warrants
Balance at December 31, 2017	$	(1,357	)
Issuances of warrants classified as derivatives		(7,577	)
Change in fair value		2,020
Exercise of warrants		565
Other, net		(212	)
Balance at June 30, 2018	$	(6,561	)

Balance at December 31, 2018	$	(1,566	)
Change in fair value		610
Balance at June 30, 2019	$	(956	)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. At June 30, 2019 and December 31, 2018, approximately $0.9 million of the derivative liability was calculated using the Black-Scholes-Merton valuation model. At June 30, 2019 and December 31, 2018, no significant amount of the derivative liability was calculated using the Monte Carlo Simulation valuation model.

The assumptions used in estimating the common stock warrant liability using the Black-Scholes-Merton valuation model as of June 30, 2019 and December 31, 2018 were as follows:

	June 30, 2019			December 31, 2018
Weighted-average risk-free interest rate		2.23	%		2.51	%
Weighted-average expected life (in years)		4.1			0.9
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		68	%		157	%

The assumptions used in estimating the common stock warrant liability using the Monte Carlo Simulation valuation model at June 30, 2019 and December 31, 2018 were as follows:

	June 30, 2019			December 31, 2018
Weighted-average risk-free interest rate		1.72	%		2.46	%
Weighted-average expected life (in years)		2.4			3.1
Expected dividend yield		-	%		-	%
Weighted average expected volatility		64	%		68	%

In addition, if any time after the second anniversary of the issuance of the warrant, both: (1) the 30-day volume weighted average price of the Company’s stock exceeds $3.00; and (2) the average daily trading volume for such 30-day period exceeds $0.4 million, the Company may call this warrant for $0.01 per share. For those warrants that have a call provision, management believes the Monte Carlo Simulation valuation model provides a better estimate of fair value for the warrants issued during 2018 and 2017 than the Black-Scholes-Merton valuation model.

Other Financial Instruments

The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Payroll and related expense	$	413	$	388
Resterilization and repackaging costs		344		344
Other		56		106
	$	813	$	838

7. Debt

L2 Capital Debt

On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with L2 Capital. The total payoff was $1.1 million, with $0.7 million in principal and $0.4 million in interest.

Hercules and MEF I, LP/Anson Investments Debt Exchange

On January 3, 2018, the Company entered into an Assignment Agreement (the “Assignment Agreement”) with MEF I, LP and Anson Investments Master Fund (collectively the “Assignees” and each an “Assignee”), Hercules Technology III, L.P. (“HT III”) and Hercules Capital, Inc. (“HC” and, together with HT III, “Hercules”), pursuant to which Hercules assigned to the Assignees all amounts remaining due under the Loan and Security Agreement, dated June 30, 2014, as amended, between the Company and Hercules (the “Loan and Security Agreement”) and (2) the note (the “Hercules Note”) between the Company and Hercules evidencing the amounts due under the Loan and Security Agreement. The total amount assigned by Hercules to the Assignees in the aggregate was $2.3 million and was secured by the same collateral underlying the Loan and Security Agreement. Subsequently, the Company entered into an exchange agreement pursuant to which the Assignees agreed to exchange the Hercules Term Loan obligation acquired by them for two senior secured convertible promissory notes issued by the Company, each in the principal amount of $1.1 million for an aggregate principal amount of $2.2 million, (the “Exchange Notes”). The Exchange Notes were scheduled to mature on February 3, 2019 (the “Maturity Date”). The Exchange Notes had interest at a rate of 15% per annum. The Exchange Notes were secured by a first priority security interest in substantially all of the Company assets, including intellectual property, and contains covenants restricting payments to certain of our affiliates.

On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with MEF I, L.P and Anson Investments. The total payoff was $1.6 million, with $1.4 million in principal and $0.2 million in interest.

North Stadium Term Loan – Related Party

On July 28, 2017, the Company entered into a $2.5 million term loan (the “North Stadium Loan”) with North Stadium Investments, LLC (“North Stadium”), a company owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board. The North Stadium Loan bore interest at 10% per annum and required the Company to make monthly interest only payments from September 5, 2017 through July 5, 2018. All principal and unpaid interest (if any) under the North Stadium Loan was due and payable on July 28, 2018. The North Stadium Loan was secured by substantially all of the Company’s assets but was junior to security interest in assets encumbered by the Hercules Term Loan (see below). In connection with the North Stadium Loan the Company also issued North Stadium a warrant to purchase up to 1,834 shares of the Company’s common stock at a purchase price of $151.20 per share, subject to a 5-year term. The relative estimated value of the warrants on the date of grant approximated $0.2 million, which was being amortized as interest expense over the life of the term loan.

On October 1, 2018, CTL Medical assumed the North Stadium Term Loan debt as part of the sale of the retail spine business. As of December 31, 2018, the Company has been released by North Stadium from any and all obligations related to this debt.

Hercules Term Loan

On June 30, 2014, the Company entered into a Loan and Security Agreement with Hercules which provided the Company with a $20.0 million term loan. The Hercules Term Loan matured on January 1, 2018. The Hercules Term Loan included a $0.2 million closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and was being amortized to interest expense over the life of the loan. The Hercules Term Loan also included a non-refundable final payment fee of $1.7 million. The final payment fee was being accrued and recorded to interest expense over the life of the loan.

On January 3, 2018, the Hercules Term Loan and all amounts owing thereunder was assigned to MEF I and Anson Investments. See discussion above under “Hercules and MEF I, LP/Anson Investments Debt Exchange” for a more detailed description of that transaction.

8. Equity

Preferred Stock Conversion

From July through December of 2018, Series B Convertible Preferred shareholders of the Company converted 10,926 shares of Series B Convertible Preferred Stock into 569,966 shares of common stock.

During May 2018 and June 2018, Series B Convertible Preferred shareholders of the Company converted a total of 4,072 shares of Series B Convertible Preferred Stock into 102,886 shares of common stock.

During June 2019, Series B Convertible Preferred shareholders of the Company converted 3,337 shares of Series B Convertible Preferred Stock into 983,528 shares of common stock.

August 2018 Warrant Exercise

During August 2018, pursuant to the cashless exercise provision contained in their warrant, L2 Capital exercised its warrants and was issued 8,069 shares of common stock. The L2 Capital warrant is no longer outstanding.

July 2018 Warrant Exercise

During May 2018, the Company closed on a public offering, consisting of both convertible preferred stock and warrants. During July 2018, 998 of the warrants were exercised and converted into 998 shares of common stock.

May 2018 Warrant Exercise (July 2016 Warrants)

During March 2018, the Company repriced 27,733 warrants dated July 8, 2016, from $360 to $63.75 (for further description see Warrant Reprice March 2018 below). During May 2018, an additional 4,861 of the repriced warrants were exercised resulting in gross proceeds to the Company of $0.3 million.

May 2018 Unit Offering

On May 14, 2018, the Company closed on an underwritten public offering of units (“the Units”), consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million, which excludes underwriting discounts and commissions and offering expenses payable by SINTX. The offering was priced at a public offering price of $1,000 per unit. Each unit consisted of one share of Series B Convertible Preferred Stock, with a stated value of $1,100, and warrants to purchase up to 25 shares of common stock (the “May 2018 Warrants”). The May 2018 Warrants are initially exercisable at an exercise price of $48 per share and expire 5 years from the date of issuance. The Series B Preferred Stock is convertible into shares of common stock by dividing the stated value of $1,100 by: (i) for the first 40 trading days following the closing of this offering, $43.54 (the “Conversion Price”), (ii) after 40 trading days but prior to the 81st trading day, the lesser of (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the 41st trading day, and (iii) after 80 trading days, the lesser of (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the date of the notice of conversion. In the case of (ii)(b) and (iii)(b) above, the share price shall not be less than $2.94 (the “Floor Price”). Each of the Conversion Price and Floor Price is subject to adjustment in certain circumstances.

The Company raised $15.0 million associated with the issuance of the Units, with $6.8 million, net of issuance costs of $0.6 million, allocated to the preferred stock and $6.9 million, net of issuance costs of $0.7 million, allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately $0.7 million of issuance costs. The 15,000 preferred shares were initially convertible into 378,997 shares of common stock and had an effective conversion rate of $43.50 per share based on the proceeds that were allocated to them. The conversion price was adjusted to $19.63, effective July 12, 2018, and was adjusted again on September 7, 2018 to $14.40. During the months ended June 30, 2019 the conversion price was adjusted down on several occasions and ultimately settled at $2.94 as of June 30, 2019.

Warrant Reprice March 2018

During the six months ended June 30, 2018 the Company entered into a warrant amendment agreement (the “Amendment Agreement”) with certain holders of previously issued Series E Common Stock Purchase Warrants (collectively, “Investors”). In connection with that certain Series E Common Stock Purchase Warrant between the Company and Investors dated July 8, 2016, the Company issued to Investors warrants to purchase up to 27,733 shares of common stock (the “Warrant Shares”) at an exercise price of $360.00 per share, (the “Investors Warrants”). Under the terms of the Amendment Agreement, in consideration of Investors exercising 22,279 of the Investors Warrants (the “Warrant Exercise”), the exercise price per share of the Investors Warrants was reduced to $63.75 per share. 22,278 of the Investors Warrants were exercised resulting in gross proceeds to the Company of $1.4 million before payment of placement agent fees and costs. In addition, and as further consideration, the Company issued to Investors new warrants to purchase up to the number of shares of common stock equal to 100% of the number of Warrant Shares issued pursuant to the Warrant Exercise at an exercise price per share equal to $60.00 per share.

June 2019 ATM Stock Offerings

During June 2019 the Company entered into an ATM equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $1.6 million. The Company sold 144,415 shares in June of 2019 raising approximately $0.4 million net of issuance cost of $0.1 million. The Company is eligible to raise an additional $1.1 million under this offering.

9. Stock-Based Compensation

A summary of the Company’s outstanding stock option activity for the six months ended June 30, 2019 is as follows:

	Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Intrinsic Value
As of December 31, 2018		377	$	7,653		6.0	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
As of June 30, 2019		377	$	7,653		5.8	$	-
Exercisable as of June 30, 2019		371	$	7,551		6.3	$	-
Expected to vest as of June 30, 2019		377	$	7,653		5.5	$	-

The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of a peer group of similar companies. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option.

10. Commitments and Contingencies

The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock options.

From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.

11. Note Receivable

On October 1, 2018, the Company completed the sale of its spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021. The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of June 30, 2019, the net carrying value of the note receivable was approximately $4.3 million.

12. Discontinued Operations

As explained in Note 1, on October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical. The gain on the sale of the retail spine business is estimated to approximate $1.4 million, which was recognized during the quarter ended December 31, 2018.

The Company and CTL Medical entered in an asset purchase agreement whereby CTL Medical agreed to acquire all of the Company’s commercial spine business for total consideration of $8.5 million, which includes a $6.0 million (including interest) note receivable (See Note 7) and CTL Medical’s assumption of the Company’s $2.5 million related party note payable to North Stadium (see Note 11). As a result of the closing, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. The Company has agreed to pay the cost, if any, to re-sterilize and re-package select silicon nitride spinal inventories sold to CTL Medical if the sterilization date expires prior to CTL Medical selling the inventories to a third-party customer. This agreement extends for a total of 24 months, ending on September 30, 2020. The Company estimates the sterilization and repackaging cost to approximate $0.5 million. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company in Salt Lake City. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.

Operating results related to discontinued operations consisted of the following for the six months ended June 30, 2018:

	Six Months Ended
	June 30, 2018
Product revenue	$	4,330
Costs of revenue		1,045
Gross profit		3,285
Operating expenses:
Research and development		717
General and administrative		348
Sales and marketing		2,264
Total operating expenses		3,329
Loss from discontinued operations	$	(44)

During the three and six months ended June 30, 2018, the Company only recorded product revenues and cost of revenues related to the spine business. Because of the sale of the retail spine business to CTL Medical, all product revenues and costs of product revenues for this period has been removed from the condensed consolidated statements of operations.

13. Leases

The Company leases office, warehouse and manufacturing space under a single operating lease, which lease originally expired during 2019 (see Note 1 under Accounting Pronouncements Adopted During the Quarter Ended June 30, 2019). On June 7, 2019, the lease was amended to extend the rental period through 2024 and reduce the amount of space leased from 54,428 square feet to 29,534 square feet. The new rent is effective the earlier of January 1, 2020 or when the Company vacates the portion of the property that will not be part of the new lease. The amended lease has two five-year extension options. As of June 30, 2019, the operating lease right-of-use asset totaled approximately $2.5 million and the operating lease liability totaled approximately $2.6 million. Non-cash operating lease expense during the six months ended June 30, 2019, totaled approximately $0.171 million. As of June 30, 2019, the weighted-average discount rate for the Company’s operating lease totaled 6.5%. During the three months ended June 30, 2019, the Company recorded a loss of approximately $0.12 million in association with the lease amendment.

Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.

Operating lease future minimum payments together with the present values as of June 30, 2019, are summarized as follows:

	June 30, 2019
2019	$	490
2020		494
2021		509
2022		525
2023		540
Thereafter		556
Total future minimum lease payments		3,114
Less amounts representing interests		(477	)
Present value of lease liability		2,637

Current-portion of operating lease liability		587
Long-term portion operating lease liability	$	2,050

14. Subsequent Events

Reverse Stock Split

On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these consolidated financial statements prior to July 26, 2019 have been adjusted retroactively to reflect the reverse stock split.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements for the year ended December 31, 2018 and the notes thereto, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed separately with the U.S. Securities and Exchange Commission. This discussion and analysis contains forward-looking statements based upon current beliefs, plans, expectations, intentions and projections that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2018, and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q.

Overview

We are an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of silicon nitride ceramics for external partners. We believe that silicon nitride has a superb combination of properties that make it ideally suited for long-term human implantation. Other biomaterials are based on bone grafts, metal alloys, and polymers- all of which have well-known practical limitations and disadvantages. In contrast, silicon nitride has a legacy of success in the most demanding and extreme industrial environments. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, among other advantages, all of which claims are validated in our large and growing inventory of peer-reviewed, published literature reports. We believe that our versatile silicon nitride manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.

We also believe that we are the first and only company to commercialize silicon nitride medical implants. Prior to October 1, 2018, we designed, manufactured and commercialized silicon nitride products for our own behalf in the spine implant market. Over 33,000 of our spinal implants manufactured with silicon nitride have been implanted into patients, with an excellent safety record. On October 1, 2018, we sold our spine implant business to CTL Medical and now manufacture spine implants made with silicon nitride for CTL Medical. Prior to selling our spine implant business to CTL Medical, we had received 510(k) regulatory clearance in the United States, a CE mark in Europe, ANVISA approval in Brazil, and ARTG and Prostheses approvals in Australia for a number of silicon nitride spine implant products designed for spinal fusion surgery. Spine implant products manufactured by us from silicon nitride are currently marketed and sold by CTL Medical under the Valeo® brand to surgeons and hospitals in the United States and to selected markets in Europe and South America. These implants are designed for use in cervical (neck) and thoracolumbar (lower back) spine surgery. We are collaborating with CTL Medical to establish a commercial partner in Australia and also working with other partners to obtain regulatory approval for silicon nitride implants in Japan.

The sale of our spine implant business to CTL Medical enables us to now focus on our core competencies. These are research and development of silicon nitride and the design and manufacture of medical and nonmedical products manufactured from silicon nitride and other ceramic materials for our own account and in collaboration with other medical device manufacturers. We are targeting original equipment manufacturer (“OEM”) – including CTL Medical - and private label partnerships in order to accelerate adoption of silicon nitride in future markets such as coating products with silicon nitride, hip and knee replacements, dental and maxillofacial implants, extremities, trauma, and sports medicine. Existing biomaterials, based on plastics, metals, and bone grafts have well-recognized limitations that we believe are addressed by silicon nitride, and we are uniquely positioned to convert existing, successful implant designs made by other companies into products manufactured with silicon nitride. OEM and private label partnerships allow us to work with a variety of partners, accelerate the adoption of silicon nitride, and realize incremental revenue at improved operating margins, when compared to the cost-intensive direct sales model.

We believe that silicon nitride addresses many of the biomaterial-related limitations in fields such as hip and knee replacements, dental and maxillofacial implants, sports medicine, extremities, and trauma surgery. We further believe that the inherent material properties of silicon nitride, and the ability to formulate the material in a variety of compositions, combined with precise control of the surface properties of the material, opens up a number of commercial opportunities across orthopedic surgery, neurological surgery, maxillofacial surgery, other medical disciplines, as well as commodity items such as industrial fasteners, bushings, and valves to addressing more complex demands of hypersonic missile radomes, aerospace, air-conditioning systems, beverage dispensers, touch-screen glass, and agribusiness fungicides.

Components of our Results of Operations

We manage our business within one reportable segment, which is consistent with how our management reviews our business, makes investment and resource allocation decisions and assesses operating performance.

Product Revenue

We derive our product revenue primarily from the manufacture and sale of spinal fusion products, used in the treatment of spine disorders, to CTL Medical, with whom we have a 10-year exclusive sales agreement in place. We are currently pursuing other sales opportunities for silicon nitride products outside the spinal fusion application. We generally recognize revenue from sales at the time the product is shipped. In general, our customers do not have any rights of return or exchange.

We believe our product revenue will increase as CTL Medical increases sales of silicon nitride spinal fusion products, as we secure other opportunities to manufacture third party products with silicon nitride, and as we continue to introduce new products into the market.

Cost of Revenue

The expenses that are included in cost of revenue include all in-house manufacturing costs for the products we manufacture.

Gross Profit

Our gross profit measures our product revenue relative to our cost of revenue. We expect our gross profit to decrease as we expand the penetration of our silicon nitride technology platform through OEM and private label partnerships, which offer additional avenues for the adoption of silicon nitride. Prior to the sale of our retail spine business, our revenues and gross profits were based on our retail sales. With the focus on OEM and private label partnerships, the margins are lower, thus causing the decrease in gross profit.

Research and Development Expenses

Our research and development costs are expensed as incurred. Research and development costs consist of engineering, product development, clinical trials, test-part manufacturing, testing, developing and validating the manufacturing process, manufacturing, facility and regulatory-related costs. Research and development expenses also include employee compensation, employee and non-employee stock-based compensation, supplies and materials, consultant services, and travel and facilities expenses related to research and development activities.

We expect to incur additional research and development costs as we continue to develop new spinal fusion products, our product candidates for total joint replacements, such as our total hip replacement product candidate, and dental applications which, may increase our total research and development expenses.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, benefits and other related costs, including stock-based compensation for certain members of our executive team and other personnel employed in finance, compliance, administrative, information technology, customer service, executive and human resource departments. General and administrative expenses also include other expenses not part of the other cost categories mentioned above, including facility expenses and professional fees for accounting and legal services.

RESULTS OF OPERATIONS

The following is a tabular presentation of our condensed consolidated operating results for the three and six months ended June 30, 2019 and 2018 (in thousands):

	Three Months Ended June 30,						$			%			Six Months Ended June 30,						$			%
	2019			2018			Change			Change			2019			2018			Change			Change
Product revenue	$	167		$	-		$	167			100	%	$	264		$	-		$	264			100	%
Cost of revenue		133			-			133			100	%		212			-			212			100	%
Gross profit		34			-			34			100	%		52			-			52			100	%
Gross profit %		20	%		-	%		20	%		100	%		20	%		0	%		20	%		100	%

Operating expenses:
Research and development		836			956			(120	)		-13	%		1,554			1,833			(279	)		-15	%
General and administrative		615			935			(320	)		-34	%		1,586			2,242			(656	)		-29	%
Sales and marketing		105			11			94			869	%		164			58			106			184	%
Total operating expenses		1,556			1,902			(347	)		-18	%		3,304			4,133			(829	)		-20	%
Loss from operations		(1,522	)		(1,902	)		380			-20	%		(3,252	)		(4,133	)		881			-21	%
Other income (expense)		792			(279	)		1,071			384	%		893			(1,533	)		2,426			158	%
Net loss before taxes		(730	)		(2,181	)		1,451			-67	%		(2,359	)		(5,666	)		3,307			58	%
Provision for income taxes		-			-			-						-			-			-
Loss – continuing		(730	)		(2,181	)		1,451			-67	%		(2,359	)		(5,666	)		3,307			58	%
Loss – discontinued		-			(131	)		131			-100	%		-			(44	)		44			-100	%
Net loss	$	(730	)	$	(2,312	)	$	1,582			68	%	$	(2,359	)	$	(5,710	)	$	3,351			59	%

Product Revenue

For the three months ended June 30, 2019, total product revenue was $0.2 million as compared to $0.0 million in the same period 2018, an increase of $0.2 million, or 100%. This increase was due to the sale of the retail spine business in October 2018 and the related restatement of revenues for the three months ended June 30, 2018 to $0.0 million as a result of the discontinued operations.

For the six months ended June 30, 2019, total product revenue was $0.3 million as compared to $0.0 million in the same period 2018, an increase of $0.3 million, or 100%. This increase was due to the sale of the retail spine business in October 2018 and the related restatement of revenues for the six months ended June 30, 2018 to $0.0 million as a result of the discontinued operations.

Cost of Revenue and Gross Profit

For the three months ended June 30, 2019, our cost of revenue increased $0.1 million, or 100%, as compared to the same period in 2018. Gross profit increased $0.03 million and gross margin percentage increased by 100%. Both increases are due to the discontinued operations treatment and the related sale of the retail spine business in October 2018.

For the six months ended June 30, 2019, our cost of revenue increased $0.2 million, or 100%, as compared to the same period in 2018. Gross profit increased $0.05 million and gross margin percentage increased by 100%. Both increases are due to the discontinued operations treatment and the related sale of the retail spine business in October 2018.

Research and Development Expenses

For the three months ended June 30, 2019, research and development expenses decreased $0.1 million, or 13%, as compared to the same period in 2018. This decrease was primarily attributable to a decrease in payroll related expenses of $0.1 million.

For the six months ended June 30, 2019, research and development expenses decreased $0.3 million, or 15%, as compared to the same period in 2018. This decrease was primarily attributable to a decrease in payroll related expenses of $0.3 million.

General and Administrative Expenses

For the three months ended June 30, 2019, general and administrative expenses decreased $0.3 million, or 34%, as compared to the same period in 2018. This decrease was primarily attributable to a decrease in accounting expenses of $0.1 million, legal fees of $0.1 million, and other expenses of $0.1 million.

For the six months ended June 30, 2019, general and administrative expenses decreased $0.7 million, or 29%, as compared to the same period in 2018. This decrease was primarily attributable to a decrease in accounting expenses of $0.2 million, legal fees of $0.2 million and other expenses of $0.3 million.

Sales and Marketing Expenses

For the three months ended June 30, 2019, sales and marketing expenses increased $0.1 million, or 869%, as compared to the same period in 2018. This increase was primarily attributable to an increase in payroll related expenses of $0.1 million.

For the six months ended June 30, 2019, sales and marketing expenses increased $0.1 million, or 184%, as compared to the same period in 2018. This increase was primarily attributable to an increase in payroll related expenses of $0.1 million.

Other Expense, Net

For the three months ended June 30, 2019, other income increased $1.1 million, or 384%, as compared to the same period in 2018. This increase was primarily due to a decrease in interest expense of $0.8 million, a decrease in offering costs of $0.7 million, and increase in interest income of $0.1 million, all offset by the change in the fair value of the derivative liabilities in the amount of $0.5 million.

For the six months ended June 30, 2019, other income increased $2.4 million, or 158%, as compared to the same period in 2018. This increase was primarily due to a decrease in the loss on the extinguishment of derivative liabilities of $1.3 million, the decrease in interest expense of $1.3 million, the decrease in the loss on extinguishment of debt of $0.3 million and the increase in interest income of $0.1 million, , a decrease in offering costs of $0.7 million, and an increase of $0.1 million on other miscellaneous accounts, all offset by the change in the fair value of the derivative liabilities in the amount of $1.4 million.

Liquidity and Capital Resources

The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering. In March 2018, the Company closed on gross proceeds of $1.4 million, before payment of placement agent fees and costs on a warrant reprice and exercise transaction. Additionally, on May 14, 2018, the Company closed on a public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. On June 4, 2019, we entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which we may sell from time to time, shares of our common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on our instructions. We have no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $1.6 million, (ii) the termination by either Maxim or us upon the provision of fifteen (15) days written notice, or (iii) June 4, 2020. We agreed to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the three months ended June 30, 2019 the Company raised $0.4 million, net of fees through the issuance of 144,415 shares of common stock under the Distribution Agreement with Maxim. The Company is eligible to raise an additional $1.1 million under this offering. In addition, the Company converted 3,337 shares of preferred stock into 983,528 shares of common stock. The Company is engaged in discussions with investment and banking firms to examine financing alternatives, including options for a public offering of the Company’s preferred or common stock. On October 1, 2018, the Company sold the retail spine business. This sale will continue to provide cash flows from July 2019 totaling $1.4 million over the next ten months and $3.5 million for the following eighteen months. The buyer also assumed the Company’s $2.5 million related party note payable.

Cash Flows

The following table summarizes, for the periods indicated, cash flows from operating, investing and financing activities (in thousands) – unaudited:

	Six Months Ended June 30,
	2019			2018
Net cash used in operating activities – continuing operations	$	(2,979	)	$	(5,532	)
Net cash used in operating activities – discontinued operations		-			(402	)
Net cash used in operating activities		(2,979	)		(5,934	)
Net cash provided by (used in) investing activities – continuing operations		680			(50	)
Net cash used in investing activities – discontinued operations		-			(107	)
Net cash provided by (used in) investing activities		680			(157	)
Net cash provided by (used in) financing activities		44			14,386
Net decrease in cash used	$	(2,255	)	$	8,295

Net Cash Used in Operating Activities

Net cash used in operating activities – continuing operations decreased $2.6 million to $3.0 million during the three months ended June 30, 2019, as compared to $5.5 million for the same period in 2018. The decrease in net cash used in operating activities – continuing operations is due to the decrease in the net loss and related non-cash add backs to the net loss during the six months ended June 30, 2019 as compared to the same period in 2018.

Net Cash Provided by Investing Activities

Net cash provided by investing activities – continuing operations increased $0.7 million to $0.7 million during the six months ended June 30, 2019, compared to net cash used in investing activities – continuing operations of $0.05 million for the same period in 2018. The increase in cash provided by investing activities – continuing operations during 2019 was primarily due to a $0.7 million increase in proceeds from notes receivable.

Net Cash Used in Financing Activities

Net cash provided by financing activities was $0.04 million during the six months ended June 30, 2019, compared to net cash provided by financing activities of $14.4 million during the same period in 2018. The $14.3 million decrease was primarily attributable to the $1.6 million net decrease in proceeds received from the exercise of common stock warrants, a decrease in proceeds from the issuance of debt of $0.7 million, a decrease in proceeds from capital offerings of $14.0 million, a $0.4 million increase in the payments of operating lease obligations, all offset by and a $2.3 million increase in payments for debt extinguishments.

Indebtedness

L2 Capital Debt

On January 31, 2018, the Company signed a promissory note in the aggregate principal amount of up to $0.84 million (the “L2 Note”) for an aggregate purchase price of up to $0.75 million and warrants to purchase up to an aggregate of 68,257 shares of common stock (the “Warrants”) at an exercise price of $3.31 per share. The maturity date was six months from date of funding. The L2 Note’s interest rate was 8% per year and a default interest rate of 18% per year. On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with L2 Capital. The total payoff was $1.1 million, with $0.7 million in principal and $0.4 million in interest.

Hercules and MEF I, LP/Anson Investments Debt Exchange

On January 3, 2018, the Company entered into an Assignment Agreement (the “Assignment Agreement”) with MEF I, LP and Anson Investments Master Fund (collectively the “Assignees” and each an “Assignee”), Hercules Technology III, L.P. (“HT III”) and Hercules Capital, Inc. (“HC” and, together with HT III, “Hercules”), pursuant to which Hercules assigned to the Assignees all amounts remaining due under the Loan and Security Agreement, dated June 30, 2014, as amended, between the Company and Hercules (the “Loan and Security Agreement”) and (2) the note (the “Hercules Note”) between the Company and Hercules evidencing the amounts due under the Loan and Security Agreement. The total amount assigned by Hercules to the Assignees in the aggregate was $2.3 million and was secured by the same collateral underlying the Loan and Security Agreement. Subsequently, the Company entered into an exchange agreement pursuant to which the Assignees agreed to exchange the Hercules Term Loan obligation acquired by them for two senior secured convertible promissory notes issued by the Company, each in the principal amount of $1.1 million for an aggregate principal amount of $2.2 million, (the “Exchange Notes”). The Exchange Notes were scheduled to mature on February 3, 2019 (the “Maturity Date”). The Exchange Notes had interest at a rate of 15% per annum. Prior to the Maturity Date, principal and interest accrued under the Exchange Notes was payable in cash or, if certain conditions were met, payable in shares of our common stock. The Exchange Notes were secured by a first priority security interest in substantially all of the Company assets, including intellectual property, and contains covenants restricting payments to certain of our affiliates.

On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with MEF I, L.P and Anson Investments. The total payoff was $1.6 million, with $1.4 million in principal and $0.2 million in interest.

North Stadium Term Loan – Related Party

Hercules Term Loan

On January 3, 2018, the Hercules Term Loan and all amounts owing thereunder was assigned to MEF I and Anson Investments. See discussion above under the heading “Hercules and MEF I, LP/Anson Investments Debt Exchange”

for a more detailed description of that transaction.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Estimates

A summary of our significant accounting policies and estimates is discussed in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in Note 1 to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018. Except as referenced in New Accounting Pronouncements below, no material changes to significant accounting policies were made during the six months ended June 30, 2019. The preparation of the financial statements in accordance with U.S. generally accepted accounting principles requires us to make judgments, estimates and assumptions regarding uncertainties that affect the reported amounts of assets and liabilities. Significant areas of uncertainty that require judgments, estimates and assumptions include the accounting for income taxes and other contingencies as well as valuation of derivative liabilities, asset impairment and collectability of accounts receivable. We use historical and other information that we consider to be relevant to make these judgments and estimates. However, actual results may differ from those estimates and assumptions that are used to prepare our financial statements.

New Accounting Pronouncements

See discussion under Note 1, Organization and Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements included in Item 1 of Part I of this Quarterly Report on Form 10-Q, for information on new accounting pronouncements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

This Report includes the certifications of our Chief Executive Officer and Principal Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to in those certifications.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are properly recorded, processed, summarized and reported within the time periods required by the Commission’s rules and forms.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (principal executive officer and principal financial officer), of the effectiveness of the design and operation of these disclosure controls and procedures, as such term is defined in Exchange Act Rule 13a-15(e), as of June 30, 2019. Based on this evaluation, the Chief Executive Officer concluded that our disclosure controls and procedures were effective as of June 30, 2019, the end of the period covered by this Quarterly Report on Form 10-Q.

As defined in SEC Regulation S-X, a material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Based on this assessment, management determined that, as of December 31, 2018, our internal control over financial reporting was not effective because of the material weaknesses described below.

The design and operating effectiveness of our controls were inadequate to ensure that complex accounting matters are always properly accounted for and reviewed in a timely manner, as outlined below:

Control Activities – The Company did not always have adequate control activities that were designed and operating effectively, including timely management review controls and controls to verify the completeness and adequacy of information prior to presentation of the information to the independent auditors.

Monitoring Activities – The Company did not always maintain effective monitoring controls related to the financial reporting process.

Our Chief Executive Officer continues with a review of our controls relating to complex accounting matters. Although our analysis is not complete, we have added additional resources with expertise in accounting for complex accounting matters. We are also considering redesigning controls to add additional layers of review and approval whenever entering into or subsequently converting, exercising, amending, repricing, exiting or otherwise experiencing changes in or to complex financial instruments.

Notwithstanding the identified material weaknesses, the Company believes the consolidated financial statements included in this Quarterly Report on Form 10-Q fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with accounting principles generally accepted in the United States of America.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the second quarter of 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are not aware of any pending or threatened legal proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property rights as well as improper hiring practices. As a result, we may be involved in various additional legal proceedings from time to time.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Filed Herewith	Incorporated by Reference herein from Form or Schedule	Filing Date	SEC File/ Reg. Number
10.1	Equity Distribution Agreement, dated as of June 4, 2019, by and between SINTX Technologies, Inc and Maxim Group LLC		Form 8-K (Exhibit 10.1)	06/04/19	001-33624

10.2	Amendment to Centrepointe Business Park Lease Agreement, dated June 7, 2019, between SINTX Technologies, Inc. and Centrepointe Properties, LLC.		Form 8-K (Exhibit 10.1)	06/10/19	001-33624

31.1	Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certificate of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

32	Certifications of the Chief Executive Officer and Principal Accounting Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101.INS	XBRL Instance Document	X

101.SCH	XBRL Taxonomy Extension Schema Document	X

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	XBRL Taxonomy Extension Label Linkbase Document	X

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SINTX Technologies, Inc. (previously known as Amedica Corporation)

Date: August 13, 2019	/s/ B. Sonny Bal
	B. Sonny Bal
	Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SINTX Technologies, Inc. (previously known as Amedica Corporation);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 13, 2019	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, B. Sonny Bal, certify that:

1. I have reviewed this quarterly report on Form 10-Q of SINTX Technologies, Inc. (previously known as Amedica Corporation);

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 13, 2019	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer and Principal Financial Officer

EX-32 4 ex32.htm

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of SINTX Technologies, Inc. (previously known as Amedica Corporation), a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The quarterly report for the quarter ended June 30, 2019 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 13, 2019	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Chief Executive Officer

	By:	/s/ B. Sonny Bal
		B. Sonny Bal
		Principal Financial Officer

EX-101.INS 5 sint-20190630.xml XBRL INSTANCE FILE 0001269026 2019-01-01 2019-06-30 0001269026 us-gaap:TrademarksMember 2019-06-30 0001269026 us-gaap:TrademarksMember 2018-12-31 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-06-30 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-06-30 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-06-30 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2019-06-30 0001269026 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2018-12-31 0001269026 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2018-12-31 0001269026 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2018-12-31 0001269026 us-gaap:FairValueMeasurementsRecurringMember SINT:CommonStockWarrantsMember 2018-12-31 0001269026 2019-06-30 0001269026 SINT:NorthStadiumInvestmentsLLCMember 2017-07-28 0001269026 SINT:NorthStadiumInvestmentsLLCMember 2017-07-27 2017-07-28 0001269026 SINT:HerculesTechnologyCapitalIncMember SINT:LoanAndSecurityAgreementMember 2014-06-29 2014-06-30 0001269026 SINT:MonteCarloSimulationValuationModelMember 2018-12-31 0001269026 SINT:WarrantsMember 2019-06-30 0001269026 SINT:MonteCarloSimulationValuationModelMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember 2019-01-01 2019-06-30 0001269026 SINT:CommonStockWarrantsMember 2017-12-31 0001269026 SINT:HerculesTechnologyCapitalIncMember SINT:LoanAndSecurityAgreementMember 2014-06-30 0001269026 SINT:MonteCarloSimulationValuationModelMember 2019-01-01 2019-06-30 0001269026 SINT:BlackScholesMertonValuationModelMember 2019-01-01 2019-06-30 0001269026 SINT:BlackScholesMertonValuationModelMember 2019-06-30 0001269026 SINT:BlackScholesMertonValuationModelMember 2018-12-31 0001269026 2018-12-31 0001269026 SINT:CommonStockWarrantsMember 2018-01-01 2018-06-30 0001269026 SINT:CommonStockWarrantsMember 2018-12-31 0001269026 SINT:L2CapitalDebtMember 2018-01-31 0001269026 SINT:HerculesTermLoanMember 2018-01-03 0001269026 SINT:HerculesTermLoanMember SINT:SeniorSecuredConvertiblePromissoryNotesOneMember 2018-01-03 0001269026 SINT:HerculesTermLoanMember SINT:SeniorSecuredConvertiblePromissoryNotesTwoMember 2018-01-03 0001269026 SINT:ExchangeNotesMember 2018-01-01 2018-01-03 0001269026 SINT:ExchangeNotesMember 2018-01-03 0001269026 SINT:HerculesTermLoanMember SINT:ClosingDateMember 2014-06-30 0001269026 us-gaap:PreferredStockMember 2018-12-31 0001269026 us-gaap:CommonStockMember 2018-12-31 0001269026 SINT:ConvertiblePreferredStockAndWarrantsMember 2018-05-13 2018-05-14 0001269026 us-gaap:IPOMember 2018-05-14 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2018-05-14 0001269026 SINT:WarrantsMember 2018-05-14 0001269026 SINT:WarrantsMember 2018-05-13 2018-05-14 0001269026 us-gaap:IPOMember 2018-05-13 2018-05-14 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember 2019-01-01 2019-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedTermMember 2018-01-01 2018-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputExpectedTermMember 2018-01-01 2018-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputExpectedTermMember 2019-01-01 2019-06-30 0001269026 2018-01-01 2018-06-30 0001269026 2018-05-13 2018-05-14 0001269026 SINT:L2CapitalDebtMember 2018-05-14 0001269026 SINT:L2CapitalDebtMember 2018-05-13 2018-05-14 0001269026 SINT:MEFILPandAnsonInvestmentsMember 2018-05-13 2018-05-14 0001269026 SINT:MEFILPandAnsonInvestmentsMember 2018-05-14 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2018-05-31 0001269026 us-gaap:CommonStockMember 2018-05-31 0001269026 2018-06-30 0001269026 2018-05-14 0001269026 us-gaap:PreferredStockMember 2018-05-14 0001269026 us-gaap:CommonStockMember 2018-05-14 0001269026 SINT:JulyTwelveTwoThousandEighteenMember 2019-06-30 0001269026 SINT:AugustTwoThousandEighteenWarrantExerciseMember SINT:SecondaryOfferingMember 2018-08-01 2018-08-31 0001269026 SINT:JulyTwoThousandEighteenWarrantExerciseMember SINT:PublicOfferingMember 2018-07-01 2018-07-31 0001269026 2018-09-07 0001269026 2019-08-12 0001269026 us-gaap:PreferredStockMember 2017-12-31 0001269026 us-gaap:CommonStockMember 2017-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001269026 us-gaap:RetainedEarningsMember 2017-12-31 0001269026 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001269026 us-gaap:RetainedEarningsMember 2018-12-31 0001269026 SINT:JulyThroughDecemberOfTwoThousandAndEighteenMember SINT:SeriesBConvertiblePreferredStockMember 2019-06-30 0001269026 SINT:JulyThroughDecemberOfTwoThousandAndEighteenMember us-gaap:CommonStockMember 2019-06-30 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2018-06-30 0001269026 us-gaap:CommonStockMember 2018-06-30 0001269026 SINT:RetailSpineBusinessMember 2018-09-29 2018-10-02 0001269026 SINT:AssetPurchaseAgreementMember 2018-09-29 2018-10-02 0001269026 SINT:AssetPurchaseAgreementMember SINT:NoninterestBearingNoteReceivableMember 2018-09-29 2018-10-02 0001269026 SINT:AssetPurchaseAgreementMember SINT:RelatedPartyNotePayableMember 2018-09-29 2018-10-02 0001269026 2018-10-02 0001269026 2018-09-29 2018-10-02 0001269026 SINT:SeriesECommonStockPurchaseWarrantMember 2018-06-30 0001269026 SINT:SeriesECommonStockPurchaseWarrantMember 2018-01-01 2018-06-30 0001269026 SINT:SeriesECommonStockPurchaseWarrantMember 2018-12-31 0001269026 SINT:NewWarrantsMember 2018-01-01 2018-06-30 0001269026 SINT:NewWarrantsMember 2018-06-30 0001269026 2018-10-31 0001269026 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember 2019-06-30 0001269026 2017-12-31 0001269026 us-gaap:PreferredStockMember 2019-01-01 2019-06-30 0001269026 us-gaap:PreferredStockMember 2019-06-30 0001269026 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001269026 us-gaap:CommonStockMember 2019-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001269026 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001269026 us-gaap:RetainedEarningsMember 2019-06-30 0001269026 us-gaap:PreferredStockMember 2018-01-01 2018-06-30 0001269026 us-gaap:PreferredStockMember 2018-06-30 0001269026 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-06-30 0001269026 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001269026 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001269026 us-gaap:RetainedEarningsMember 2018-06-30 0001269026 SINT:CommonStockWarrantsMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember 2018-06-30 0001269026 SINT:RetailSpineBusinessMember 2018-10-01 2018-12-31 0001269026 2019-01-02 0001269026 2019-01-01 2019-01-02 0001269026 2019-04-01 2019-06-30 0001269026 2018-04-01 2018-06-30 0001269026 us-gaap:CommonStockMember 2018-06-30 0001269026 SINT:WarrantDerivativeMember 2018-01-01 2018-06-30 0001269026 us-gaap:SubsequentEventMember 2019-07-25 2019-07-26 0001269026 2018-03-01 2018-03-31 0001269026 us-gaap:PreferredStockMember 2019-04-01 2019-06-30 0001269026 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001269026 us-gaap:SubsequentEventMember SINT:RetailSpineBusinessMember SINT:NextTenMonthsMember 2019-07-01 2019-07-31 0001269026 us-gaap:SubsequentEventMember SINT:RetailSpineBusinessMember SINT:FollowingEighteenMonthsMember 2019-07-01 2019-07-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2018-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:BlackScholesMertonValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember 2018-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputExpectedDividendRateMember 2018-12-31 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember 2019-06-30 0001269026 SINT:CommonStockWarrantsMember SINT:MonteCarloSimulationValuationModelMember us-gaap:MeasurementInputOptionVolatilityMember 2018-12-31 0001269026 SINT:SeriesBConvertiblePreferredStockMember 2019-06-30 0001269026 us-gaap:CommonStockMember 2019-06-30 0001269026 SINT:MayTwoThousandEighteenWarrantExerciseMember 2018-03-31 0001269026 SINT:MayTwoThousandEighteenWarrantExerciseMember srt:MinimumMember 2018-03-31 0001269026 SINT:MayTwoThousandEighteenWarrantExerciseMember srt:MaximumMember 2018-03-31 0001269026 SINT:MayTwoThousandEighteenWarrantExerciseMember 2018-05-31 0001269026 SINT:MayTwoThousandEighteenWarrantExerciseMember 2018-05-01 2018-05-31 0001269026 2018-10-01 2018-10-31 0001269026 2019-06-06 2019-06-07 0001269026 2019-06-07 0001269026 SINT:EquityDistributionAgreementMember srt:MaximumMember 2019-06-03 2019-06-04 0001269026 SINT:EquityDistributionAgreementMember 2019-06-03 2019-06-04 0001269026 SINT:ATMEquityDistributionAgreementMember srt:MaximumMember 2019-01-01 2019-06-30 0001269026 SINT:ATMEquityDistributionAgreementMember 2019-01-01 2019-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft Sintx Technologies, Inc. 10-Q 2019-06-30 false --12-31 Non-accelerated Filer

956000

1566000

502000

504000

6000

56000

0.01

1100

250000000

1854898

726455

1854898

726455

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements as of June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">956</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">956</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements as of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,566</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,566</td><td style="width: 1%; text-align: left"> </td></tr></table>

737

4074

0001269026

0.01

1100

130000000

737

4074

2282000

1100000

1600000

7577000

1400000

300000

900000

The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended June 30, 2019 and 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,357</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuances of warrants classified as derivatives</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,577</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(212</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,561</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2018</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,566</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">610</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(956</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr></table>

2500000

20000000

840000

2300000

1100000

2200000

700000

1400000

151.20

3.31

360.00

63.75

60.00

360

63.75

0.10

0.08

0.15

0.10

2021-10-01

2018-07-28

2018-01-01

2019-02-03

2.94

43.54

43.50

19.63

14.40

27733

4861

The assumptions used in estimating the common stock warrant liability using the Monte Carlo Simulation valuation model at June 30, 2019 and December 31, 2018 were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1.72</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.46</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left">%</td></tr></table>

The assumptions used in estimating the common stock warrant liability using the Black-Scholes-Merton valuation model as of June 30, 2019 and December 31, 2018 were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.23</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.51</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157</td><td style="text-align: left">%</td></tr></table>

6754000

6800000

4. Intangible Assets   Intangible assets consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Trademarks</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">44</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Inventories consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">596</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">624</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intermediate goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WIP</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">681</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Accrued liabilities consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">413</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">388</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Resterilization and repackaging costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">344</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">344</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">813</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

true false false

6440000

8399000

7000

11309000

1000

226070000

-220629000

237673000

-229281000

5442000

18000

238062000

-231640000

237646000

-226339000

2000

-2359000

-5710000

-2359000

-5711000

-730000

-2312000

Operating results related to discontinued operations consisted of the following for the six months ended June 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2018</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="width: 78%; font: 10pt Times New Roman, Times, Serif">Product revenue</td> <td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 18%; text-align: right; font: 10pt Times New Roman, Times, Serif">4,330</td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Costs of revenue</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,045</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Gross profit</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,285</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Operating expenses:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Research and development</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">717</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">General and administrative</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">348</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Sales and marketing</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,264</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Total operating expenses</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,329</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(44)</td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr></table>

4330000

1045000

3285000

717000

348000

2264000

3329000

-44000

A summary of the Company’s outstanding stock option activity for the six months ended June 30, 2019 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">As of December 31, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">377</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">6.0</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">   -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">As of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,653</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable as of June 30, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">371</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected to vest as of June 30, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr></table>

2019 1957930

1399000

1084000

15000000

600000

700000

50000

6000

4000

44000

46000

3.00

0.01

2.94

400000

1357000

1566000

956000

6561000

-212000

P4Y1M6D P10M25D P3Y1M6D P2Y4M24D 750000

1834

68257

0.18

The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021.

15000000

400000

200000

0.875

200000

1700000

4072

102886

15000

378997

10926

569966

4072

102886

3337

983528

8069 998 998 22279

1000

P5Y

600000

377

7653

P6Y

P5Y9M18D

P6Y3M19D

P5Y6M

1000

34000

98000

1000

34000

1000

34000

1040000 1040000 -9000 -9000

1400000

8500000

6000000

2500000

500000

194444

138889

1.00

-107000

915725

-2359000

-5666000

-730000

-2181000

-4717000

-13044000

-3088000

-9646000

609000 362000 632000 1610000

-609000

-362000

-632000

-1610000

-2968000

-6028000

-1362000

-3791000

-44000

-131000

-5326000

-13406000

-3720000

-11256000

829724

154545

931859

194933

119421

829724

154545

931859

314354

-2.84

-36.66

-0.78

-11.19

-0.28

-0.67

-2.84 -47.46 -2.53 -37.62

-5.68

-84.40

-3.31

-49.48

-3.58

-39.01

-1.46

-12.06

-0.28

-0.42

-2.84 -47.46 -2.53 -23.33

-6.42

-86.75

-3.99

-35.81

2358000 7334000 2358000 7334000

Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(730</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(632</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,362</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,088</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(632</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,720</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">931,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">931,859</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.78</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.46</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.53</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.53</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.31</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.99</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,359</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(609</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,968</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(609</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,326</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">829,724</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">829,724</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2.84</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3.58</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5.68</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6.42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   Below are basic and diluted loss per share data for the three months ended June 30, 2018, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,181</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(3,791</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Income from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,646</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,610</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,256</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">194,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,354</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(12.06</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.67</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.42</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37.62</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.33</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(49.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(35.81</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   Below are basic and diluted loss per share data for the six months ended June 30, 2018, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(5,666</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(362</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,028</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Income from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(44</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,044</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(362</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,406</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,545</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(36.66</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(39.01</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.28</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.28</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47.46</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47.46</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(84.40</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(86.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr></table>

264000

167000

212000

133000

52000

34000

1554000

1833000

836000

956000

1586000

2242000

615000

935000

164000

58000

105000

11000

3304000

4133000

1556000

1902000

-3252000

-4133000

-1522000

-1902000

237000

115000

-340000

-1252000

48000

5000

48000

3000

893000

-1533000

792000

-279000

-2359000

-5666000

-730000

-2181000

2358000

7334000

2358000

7334000

-0.28

-0.67

-0.28

-0.42

829724

154545

931859

314354

600000

371

377

7551

7653

6900 700000 -44000 -131000

-2359000

-5666000

-730000

-2181000

1400000

3500000

2500000

2535000

659000

2637000

946000

2704000 659000

0.065

413000

388000

344000 344000

56000

106000

596000

624000

9000

76000

47000

5000

3192000

5447000

173000

263000

234000

171000

85000

52000

5083000

7017000

596000

624000

87000

124000

44000

46000

2897000

3669000

35000

11277000

11515000

295000

301000

813000

838000

454000

1062000

587000

169000

23000

10000

2172000

2380000

113000

232000

4837000

3116000

19000

7000

238062000

237673000

-231641000

-229281000

11277000

11515000

1453000 1453000 Yes Yes false

2050000

2000

1284000

2000

809000

-2.84 -47.46 -2.53 -23.33 -2.84 -47.46 -2.53 -37.62

610000

2020000

631000

1209000

15 6754000 6754000

-3337

983528

-4

102886

3337

983528

10000

-10000

1000

-1000

4074

726455

100935

737

1854898

250308

19348 7334000 7334000 -7334000 -7334000

144415

397000

1000

396000

397000

1000 1000

131000

668000

682000

100000

52000

53000

2000

28000

237000

812000

9000

-79000

63000

76000

5000

-19000

-241000

-2979000

-5532000

-402000

-2979000

-5934000

695000

50000

680000

-50000

680000

-157000

1000

1633000

397000

354000

705000

44000

14387000

3192000

5447000

8835000

539000

1000 565000 98000

2000

337000

-51000

15000

682000

-2255000

8296000

171000

-99000

1400000

-44000

-131000

1 for 30 reverse stock split

0.0223

0.0251

0.00

0.68

1.57

0.0172

0.0246

0.00

0.64

0.68

The Series B Preferred Stock is convertible into shares of common stock by dividing the stated value of $1,100 by: (i) for the first 40 trading days following the closing of this offering, $43.54 (the "Conversion Price"), (ii) after 40 trading days but prior to the 81st trading day, the lesser of (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the 41st trading day, and (iii) after 80 trading days, the lesser of (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the date of the notice of conversion. In the case of (ii)(b) and (iii)(b) above, the share price shall not be less than $2.94 (the "Floor Price"). Each of the Conversion Price and Floor Price is subject to adjustment in certain circumstances.

The Company leases office, warehouse and manufacturing space under a single operating lease, which lease originally expired during 2019

The amended lease has two five-year extension options.

On June 7, 2019, the lease was amended to extend the rental period through 2024

54428

29534

490000

494000

509000

525000

540000

556000

3114000

477000

610000

2020000

120000

-7577000

565000

Operating lease future minimum payments together with the present values as of June 30, 2019, are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">490</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">494</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">509</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">525</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">540</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,114</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less amounts representing interests</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(477</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Present value of lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,637</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current-portion of operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">587</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term portion operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of June 30, 2019, the net carrying value of the note receivable was approximately $4.3 million.

-2358000 -7334000 -2358000 -7334000

2265000

1453000

1. Organization and Summary of Significant Accounting Policies   Organization   SINTX Technologies, Inc. (“SINTX” or “the Company”) (previously known as Amedica Corporation) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Company’s products are primarily sold in the United States.   As further explained in Note 12, On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical, a Dallas, Texas-based privately held medical device manufacturer. As a result of the sale, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.   On October 30, 2018, the Company amended its Certificate of Incorporation with the State of Delaware to change its corporate name to SINTX Technologies, Inc. in order to better reflect its focus on silicon nitride science and technologies and pipeline of silicon nitride-based products in various biomedical applications. The Company also changed its trading symbol on the NASDAQ Capital Market to “SINT”. The Company also changed the name of its wholly owned subsidiary US Spine, Inc. to “ST Sub, Inc.”   The previous name, Amedica, has transferred to CTL Medical, which is now CTL-Amedica. The Company’s new corporate brand reflects both the Company’s core competence in the science and production of silicon nitride ceramics, as well as encouraging prospects for the future, as an OEM supplier of spine implants to CTL-Amedica, and several opportunities outside of spine. The Company will focus on developing silicon nitride in terms of product design, and future biomaterial formulations, for a variety of OEM customers.   As further explained in Note 14, the Company effected a 1 for 30 reverse stock split of the Company’s common stock on July 26, 2019.   Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company and its wholly owned subsidiary, ST Sub, Inc. All material intercompany transactions and balances have been eliminated in consolidation. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 11, 2019. The results of operations for the six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2018.   Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the periods then ended. Actual results could differ from those estimates. The most significant estimates relate to inventory, long-lived and intangible assets and the liability for preferred stock and common stock warrants.   Liquidity and Capital Resources   The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.   For the six months ended June 30, 2019 and 2018, the Company incurred net losses from continuing operations of approximately $2.4 million and $5.7 million, respectively, and used cash in continuing operations of approximately $3.0 million and $5.5 million, respectively. The Company had an accumulated deficit of approximately $232 million and $229 million as of June 30, 2019 and December 31, 2018, respectively. To date, the Company’s operations have been principally financed by proceeds received from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operating activities. The Company’s continuation as a going concern is dependent upon its ability to increase sales and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operating activities or obtain additional financing is uncertain.   The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of the Company’s silicon nitride material are not well known, and the Company believes that the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.   The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering. In March 2018, the Company closed on gross proceeds of $1.4 million, before payment of placement agent fees and costs on a warrant reprice and exercise transaction. Additionally, on May 14, 2018, the Company closed on a public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of our common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $1.6 million, (ii) the termination by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) June 4, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the three months ended June 30, 2019 the Company raised $0.397 million, net of fees through the issuance of 144,415 shares of common stock under the Distribution Agreement with Maxim. The Company is eligible to raise an additional $1.2 million under this offering. In addition, the Company converted 3,337 shares of preferred stock into 983,528 shares of common stock. The Company is engaged in discussions with investment and banking firms to examine financing alternatives, including options for a public offering of the Company’s preferred or common stock. On October 1, 2018, the Company sold the retail spine business. This sale will continue to provide cash flows from July 2019 totaling $1.4 million over the next ten months and $3.5 million for the following eighteen months. The buyer also assumed the Company’s $2.5 million related party note payable.   Although the Company is seeking to obtain additional equity and/or debt financing, such funding is not assured and may not be available to the Company on favorable or acceptable terms and may involve significant restrictive covenants. Any additional equity financing is also not assured and, if available to the Company, will most likely be dilutive to its current stockholders. If the Company is not able to obtain additional debt or equity financing on a timely basis, the impact on the Company will be material and adverse.   These uncertainties create substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.   Significant Accounting Policies   Except as explained below, no material changes were made to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.   Accounting Pronouncements Adopted During the Quarter Ended June 30, 2019   In August 2016, the FASB updated accounting guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Under prior U.S. GAAP, there was no specific guidance on the eight cash flow classification issues aforementioned. The Company adopted the new guidance effective January 1, 2019. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption.   In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The Company adopted the new guidance effective January 1, 2019 (see Note 13), using the modified retrospective approach. Adoption of the new guidance resulted in the Company being required to record an additional operating lease right-of-use asset totaling approximately $0.659 million and liability totaling approximately $0.946 million (with $0.659 million incremental to adoption of the new guidance) on the date of adoption. Subsequent to the initial adoption of the new standard the Company amended the lease (see Note 13). The standard did not materially impact the consolidated net loss and had no impact on cash flows.   In May 2014, in addition to several amendments issued during 2016, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The Company adopted the new guidance effective January 1, 2019. The core principle of the new guidance is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates are often required within the revenue recognition process than were required under prior U.S. GAAP. The Company has one primary customer (see Note 12) and related contract that has one performance obligation to which revenue is allocated. Revenue under this contract is recognized when the product is shipped to the customer. The Company generally bills its customer upon shipment of the product and invoices are generally due within 30 days. The Company does provide certain rights of return, which historically have not been significant. The Company does not anticipate incurring significant incremental costs to obtain contracts with future customers. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption.   New Accounting Pronouncements Not Yet Adopted   The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

2. Basic and Diluted Net Loss per Common Share   Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period that are determined to be dilutive. Common stock equivalents are primarily comprised of preferred stock, warrants for the purchase of common stock and stock options. The Company had potentially dilutive securities, totaling approximately 0.6 million and 0.7 million as of June 30, 2019 and 2018, respectively.   Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(730</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(632</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,362</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,088</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(632</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,720</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">931,859</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">931,859</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.78</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1.46</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.53</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.53</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.31</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3.99</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,359</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(609</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,968</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,358</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,717</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(609</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,326</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">829,724</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">829,724</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2.84</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3.58</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2.84</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5.68</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6.42</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   Below are basic and diluted loss per share data for the three months ended June 30, 2018, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,181</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(1,610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(3,791</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Income from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(131</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,646</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,610</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(11,256</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">194,933</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,421</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314,354</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(11.19</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(12.06</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.67</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.42</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(37.62</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23.33</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(49.48</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(35.81</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   Below are basic and diluted loss per share data for the six months ended June 30, 2018, which are in thousands except for share and per share data:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Basic Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effect of Dilutive Warrant Securities</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Diluted Calculation</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 46%; text-align: left; padding-left: 10pt">Loss from continuing operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(5,666</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(362</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,028</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Income from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(44</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(44</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,334</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,044</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(362</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,406</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Number of shares used in per common share calculations:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,545</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Net loss per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Loss from continuing operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(36.66</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(39.01</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.28</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.28</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend and accretion of a discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47.46</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(47.46</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net loss attributable to common stockholders</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(84.40</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(86.75</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr></table>

3. Inventories   Inventories consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">596</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">624</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Intermediate goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>WIP</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">681</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   As of June 30, 2019, inventories totaling approximately $0.08 million and $0.6 million were classified as current and long-term, respectively. Inventories classified as current represent the carrying value of inventories as of June 30, 2019, that management estimates will be sold by June 30, 2020.

5. Fair Value Measurements   Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis   The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 0.75in; font: 10pt Times New Roman, Times, Serif">Level 1 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">quoted market prices for identical assets or liabilities in active markets.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Level 2 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">observable prices that are based on inputs not quoted on active markets but corroborated by market data.</td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">Level 3 -</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</td></tr> </table>   The Company classifies assets and liabilities measured at fair value in their entirety based on the lowest level of input that is significant to their fair value measurement. No financial assets were measured on a recurring basis as of June 30, 2019 and December 31, 2018. The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2019 and December 31, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements as of June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">956</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">956</td><td style="width: 1%; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value Measurements as of December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Derivative liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 36%; text-align: left; padding-left: 10pt">Common stock warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,566</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,566</td><td style="width: 1%; text-align: left"> </td></tr> </table>   The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended June 30, 2019 and 2018.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance at December 31, 2017</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,357</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Issuances of warrants classified as derivatives</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,577</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,020</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise of warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">565</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other, net</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(212</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2018</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,561</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at December 31, 2018</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(1,566</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">610</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance at June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(956</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>   Common Stock Warrants   The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. At June 30, 2019 and December 31, 2018, approximately $0.9 million of the derivative liability was calculated using the Black-Scholes-Merton valuation model. At June 30, 2019 and December 31, 2018, no significant amount of the derivative liability was calculated using the Monte Carlo Simulation valuation model.   The assumptions used in estimating the common stock warrant liability using the Black-Scholes-Merton valuation model as of June 30, 2019 and December 31, 2018 were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.23</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.51</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157</td><td style="text-align: left">%</td></tr> </table>   The assumptions used in estimating the common stock warrant liability using the Monte Carlo Simulation valuation model at June 30, 2019 and December 31, 2018 were as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Weighted-average risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1.72</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">2.46</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.1</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Weighted average expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">68</td><td style="text-align: left">%</td></tr> </table>   In addition, if any time after the second anniversary of the issuance of the warrant, both: (1) the 30-day volume weighted average price of the Company’s stock exceeds $3.00; and (2) the average daily trading volume for such 30-day period exceeds $0.4 million, the Company may call this warrant for $0.01 per share. For those warrants that have a call provision, management believes the Monte Carlo Simulation valuation model provides a better estimate of fair value for the warrants issued during 2018 and 2017 than the Black-Scholes-Merton valuation model.   Other Financial Instruments   The Company’s recorded values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The recorded value of notes payable approximates the fair value as the interest rate approximates market interest rates.

6. Accrued Liabilities   Accrued liabilities consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll and related expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">413</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">388</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Resterilization and repackaging costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">344</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">344</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">56</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">106</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">813</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

7. Debt   L2 Capital Debt   On January 31, 2018, the Company signed a promissory note in the aggregate principal amount of up to $0.84 million (the “L2 Note”) for an aggregate purchase price of up to $0.75 million and warrants to purchase up to an aggregate of 68,257 shares of common stock (the “Warrants”) at an exercise price of $3.31 per share. The maturity date was six months from date of funding. The L2 Note’s interest rate was 8% per year and a default interest rate of 18% per year.   On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with L2 Capital. The total payoff was $1.1 million, with $0.7 million in principal and $0.4 million in interest.   Hercules and MEF I, LP/Anson Investments Debt Exchange   On January 3, 2018, the Company entered into an Assignment Agreement (the “Assignment Agreement”) with MEF I, LP and Anson Investments Master Fund (collectively the “Assignees” and each an “Assignee”), Hercules Technology III, L.P. (“HT III”) and Hercules Capital, Inc. (“HC” and, together with HT III, “Hercules”), pursuant to which Hercules assigned to the Assignees all amounts remaining due under the Loan and Security Agreement, dated June 30, 2014, as amended, between the Company and Hercules (the “Loan and Security Agreement”) and (2) the note (the “Hercules Note”) between the Company and Hercules evidencing the amounts due under the Loan and Security Agreement. The total amount assigned by Hercules to the Assignees in the aggregate was $2.3 million and was secured by the same collateral underlying the Loan and Security Agreement. Subsequently, the Company entered into an exchange agreement pursuant to which the Assignees agreed to exchange the Hercules Term Loan obligation acquired by them for two senior secured convertible promissory notes issued by the Company, each in the principal amount of $1.1 million for an aggregate principal amount of $2.2 million, (the “Exchange Notes”). The Exchange Notes were scheduled to mature on February 3, 2019 (the “Maturity Date”). The Exchange Notes had interest at a rate of 15% per annum. The Exchange Notes were secured by a first priority security interest in substantially all of the Company assets, including intellectual property, and contains covenants restricting payments to certain of our affiliates.   On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with MEF I, L.P and Anson Investments. The total payoff was $1.6 million, with $1.4 million in principal and $0.2 million in interest.   North Stadium Term Loan – Related Party   On July 28, 2017, the Company entered into a $2.5 million term loan (the “North Stadium Loan”) with North Stadium Investments, LLC (“North Stadium”), a company owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board. The North Stadium Loan bore interest at 10% per annum and required the Company to make monthly interest only payments from September 5, 2017 through July 5, 2018. All principal and unpaid interest (if any) under the North Stadium Loan was due and payable on July 28, 2018. The North Stadium Loan was secured by substantially all of the Company’s assets but was junior to security interest in assets encumbered by the Hercules Term Loan (see below). In connection with the North Stadium Loan the Company also issued North Stadium a warrant to purchase up to 1,834 shares of the Company’s common stock at a purchase price of $151.20 per share, subject to a 5-year term. The relative estimated value of the warrants on the date of grant approximated $0.2 million, which was being amortized as interest expense over the life of the term loan.   On October 1, 2018, CTL Medical assumed the North Stadium Term Loan debt as part of the sale of the retail spine business. As of December 31, 2018, the Company has been released by North Stadium from any and all obligations related to this debt.   Hercules Term Loan   On June 30, 2014, the Company entered into a Loan and Security Agreement with Hercules which provided the Company with a $20.0 million term loan. The Hercules Term Loan matured on January 1, 2018. The Hercules Term Loan included a $0.2 million closing fee, which was paid to Hercules on the closing date of the loan. The closing fee was recorded as a debt discount and was being amortized to interest expense over the life of the loan. The Hercules Term Loan also included a non-refundable final payment fee of $1.7 million. The final payment fee was being accrued and recorded to interest expense over the life of the loan.   On January 3, 2018, the Hercules Term Loan and all amounts owing thereunder was assigned to MEF I and Anson Investments. See discussion above under “Hercules and MEF I, LP/Anson Investments Debt Exchange” for a more detailed description of that transaction.

8. Equity   Preferred Stock Conversion   From July through December of 2018, Series B Convertible Preferred shareholders of the Company converted 10,926 shares of Series B Convertible Preferred Stock into 569,966 shares of common stock.   During May 2018 and June 2018, Series B Convertible Preferred shareholders of the Company converted a total of 4,072 shares of Series B Convertible Preferred Stock into 102,886 shares of common stock.   During June 2019, Series B Convertible Preferred shareholders of the Company converted 3,337 shares of Series B Convertible Preferred Stock into 983,528 shares of common stock.   August 2018 Warrant Exercise   During August 2018, pursuant to the cashless exercise provision contained in their warrant, L2 Capital exercised its warrants and was issued 8,069 shares of common stock. The L2 Capital warrant is no longer outstanding.   July 2018 Warrant Exercise   During May 2018, the Company closed on a public offering, consisting of both convertible preferred stock and warrants. During July 2018, 998 of the warrants were exercised and converted into 998 shares of common stock.   May 2018 Warrant Exercise (July 2016 Warrants)   During March 2018, the Company repriced 27,733 warrants dated July 8, 2016, from $360 to $63.75 (for further description see Warrant Reprice March 2018 below). During May 2018, an additional 4,861 of the repriced warrants were exercised resulting in gross proceeds to the Company of $0.3 million.   May 2018 Unit Offering   On May 14, 2018, the Company closed on an underwritten public offering of units (“the Units”), consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million, which excludes underwriting discounts and commissions and offering expenses payable by SINTX. The offering was priced at a public offering price of $1,000 per unit. Each unit consisted of one share of Series B Convertible Preferred Stock, with a stated value of $1,100, and warrants to purchase up to 25 shares of common stock (the “May 2018 Warrants”). The May 2018 Warrants are initially exercisable at an exercise price of $48 per share and expire 5 years from the date of issuance. The Series B Preferred Stock is convertible into shares of common stock by dividing the stated value of $1,100 by: (i) for the first 40 trading days following the closing of this offering, $43.54 (the “Conversion Price”), (ii) after 40 trading days but prior to the 81st trading day, the lesser of  (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the 41st trading day, and (iii) after 80 trading days, the lesser of  (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the date of the notice of conversion. In the case of (ii)(b) and (iii)(b) above, the share price shall not be less than $2.94 (the “Floor Price”). Each of the Conversion Price and Floor Price is subject to adjustment in certain circumstances.   The Company raised $15.0 million associated with the issuance of the Units, with $6.8 million, net of issuance costs of $0.6 million, allocated to the preferred stock and $6.9 million, net of issuance costs of $0.7 million, allocated to the warrants. In association with the warrants that were recorded as a derivative liability, the Company immediately expensed approximately $0.7 million of issuance costs. The 15,000 preferred shares were initially convertible into 378,997 shares of common stock and had an effective conversion rate of $43.50 per share based on the proceeds that were allocated to them. The conversion price was adjusted to $19.63, effective July 12, 2018, and was adjusted again on September 7, 2018 to $14.40. During the months ended June 30, 2019 the conversion price was adjusted down on several occasions and ultimately settled at $2.94 as of June 30, 2019.   Warrant Reprice March 2018   During the six months ended June 30, 2018 the Company entered into a warrant amendment agreement (the “Amendment Agreement”) with certain holders of previously issued Series E Common Stock Purchase Warrants (collectively, “Investors”). In connection with that certain Series E Common Stock Purchase Warrant between the Company and Investors dated July 8, 2016, the Company issued to Investors warrants to purchase up to 27,733 shares of common stock (the “Warrant Shares”) at an exercise price of $360.00 per share, (the “Investors Warrants”). Under the terms of the Amendment Agreement, in consideration of Investors exercising 22,279 of the Investors Warrants (the “Warrant Exercise”), the exercise price per share of the Investors Warrants was reduced to $63.75 per share. 22,278 of the Investors Warrants were exercised resulting in gross proceeds to the Company of $1.4 million before payment of placement agent fees and costs. In addition, and as further consideration, the Company issued to Investors new warrants to purchase up to the number of shares of common stock equal to 100% of the number of Warrant Shares issued pursuant to the Warrant Exercise at an exercise price per share equal to $60.00 per share.   June 2019 ATM Stock Offerings During June 2019 the Company entered into an ATM equity distribution agreement in which the Company may sell, from time to time, shares of common stock having an aggregate offering price of up to $1.6 million. The Company sold 144,415 shares in June of 2019 raising approximately $0.4 million net of issuance cost of $0.1 million. The Company is eligible to raise an additional $1.1 million under this offering.

9. Stock-Based Compensation   A summary of the Company’s outstanding stock option activity for the six months ended June 30, 2019 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Weighted- Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%">As of December 31, 2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">377</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">7,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">6.0</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">   -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">As of June 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">377</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,653</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">5.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable as of June 30, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">371</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,551</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Expected to vest as of June 30, 2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">377</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">7,653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table>   The Company estimates the fair value of each stock option on the grant date using the Black-Scholes-Merton valuation model, which requires several estimates including an estimate of the fair value of the underlying common stock on grant date. The expected volatility was based on an average of the historical volatility of a peer group of similar companies. The expected term was calculated utilizing the simplified method. The risk-free interest rate was based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option.

10. Commitments and Contingencies   The Company has executed agreements with certain executive officers of the Company which, upon the occurrence of certain events related to a change in control, call for payments to the executives up to three times their annual salary and accelerated vesting of previously granted stock options.   From time to time, the Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. Management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results or cash flows.

11. Note Receivable   On October 1, 2018, the Company completed the sale of its spine business to CTL Medical. The sale included a $6 million noninterest bearing note receivable. The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021. The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of June 30, 2019, the net carrying value of the note receivable was approximately $4.3 million.

12. Discontinued Operations   As explained in Note 1, on October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical. The gain on the sale of the retail spine business is estimated to approximate $1.4 million, which was recognized during the quarter ended December 31, 2018.   The Company and CTL Medical entered in an asset purchase agreement whereby CTL Medical agreed to acquire all of the Company’s commercial spine business for total consideration of $8.5 million, which includes a $6.0 million (including interest) note receivable (See Note 7) and CTL Medical’s assumption of the Company’s $2.5 million related party note payable to North Stadium (see Note 11). As a result of the closing, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. The Company has agreed to pay the cost, if any, to re-sterilize and re-package select silicon nitride spinal inventories sold to CTL Medical if the sterilization date expires prior to CTL Medical selling the inventories to a third-party customer. This agreement extends for a total of 24 months, ending on September 30, 2020. The Company estimates the sterilization and repackaging cost to approximate $0.5 million. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company in Salt Lake City. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.   Operating results related to discontinued operations consisted of the following for the six months ended June 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Six Months Ended</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"> </td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2018</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="width: 78%; font: 10pt Times New Roman, Times, Serif">Product revenue</td> <td style="width: 2%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif">$</td> <td style="width: 18%; text-align: right; font: 10pt Times New Roman, Times, Serif">4,330</td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Costs of revenue</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,045</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Gross profit</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,285</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif">Operating expenses:</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Research and development</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">717</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">General and administrative</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">348</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif">Sales and marketing</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,264</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Total operating expenses</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,329</td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif">$</td> <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(44)</td> <td style="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>   During the three and six months ended June 30, 2018, the Company only recorded product revenues and cost of revenues related to the spine business. Because of the sale of the retail spine business to CTL Medical, all product revenues and costs of product revenues for this period has been removed from the condensed consolidated statements of operations.

13. Leases   The Company leases office, warehouse and manufacturing space under a single operating lease, which lease originally expired during 2019 (see Note 1 under Accounting Pronouncements Adopted During the Quarter Ended June 30, 2019). On June 7, 2019, the lease was amended to extend the rental period through 2024 and reduce the amount of space leased from 54,428 square feet to 29,534 square feet. The new rent is effective the earlier of January 1, 2020 or when the Company vacates the portion of the property that will not be part of the new lease. The amended lease has two five-year extension options. As of June 30, 2019, the operating lease right-of-use asset totaled approximately $2.5 million and the operating lease liability totaled approximately $2.6 million. Non-cash operating lease expense during the six months ended June 30, 2019, totaled approximately $0.171 million. As of June 30, 2019, the weighted-average discount rate for the Company’s operating lease totaled 6.5%. During the three months ended June 30, 2019, the Company recorded a loss of approximately $0.12 million in association with the lease amendment.   Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company accounts for lease components separately from the non-lease components. The depreciable life of the assets and leasehold improvements are limited by the expected lease term.   Operating lease future minimum payments together with the present values as of June 30, 2019, are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">490</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">494</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">509</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">525</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">540</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left">Thereafter</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">556</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Total future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,114</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Less amounts representing interests</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(477</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Present value of lease liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,637</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Current-portion of operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">587</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Long-term portion operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,050</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

14. Subsequent Events   Reverse Stock Split   On July 26, 2019 the Company effected a 1 for 30 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All common stock shares, equivalents, and per-share amounts for all periods presented in these consolidated financial statements prior to July 26, 2019 have been adjusted retroactively to reflect the reverse stock split.

Organization   SINTX Technologies, Inc. (“SINTX” or “the Company”) (previously known as Amedica Corporation) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Company’s products are primarily sold in the United States.   As further explained in Note 12, On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical, a Dallas, Texas-based privately held medical device manufacturer. As a result of the sale, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products.   On October 30, 2018, the Company amended its Certificate of Incorporation with the State of Delaware to change its corporate name to SINTX Technologies, Inc. in order to better reflect its focus on silicon nitride science and technologies and pipeline of silicon nitride-based products in various biomedical applications. The Company also changed its trading symbol on the NASDAQ Capital Market to “SINT”. The Company also changed the name of its wholly owned subsidiary US Spine, Inc. to “ST Sub, Inc.”   The previous name, Amedica, has transferred to CTL Medical, which is now CTL-Amedica. The Company’s new corporate brand reflects both the Company’s core competence in the science and production of silicon nitride ceramics, as well as encouraging prospects for the future, as an OEM supplier of spine implants to CTL-Amedica, and several opportunities outside of spine. The Company will focus on developing silicon nitride in terms of product design, and future biomaterial formulations, for a variety of OEM customers.   As further explained in Note 14, the Company effected a 1 for 30 reverse stock split of the Company’s common stock on July 26, 2019.

Basis of Presentation   These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company and its wholly owned subsidiary, ST Sub, Inc. All material intercompany transactions and balances have been eliminated in consolidation. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 11, 2019. The results of operations for the six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2018.

Use of Estimates   The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the periods then ended. Actual results could differ from those estimates. The most significant estimates relate to inventory, long-lived and intangible assets and the liability for preferred stock and common stock warrants.

Liquidity and Capital Resources   The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements.   For the six months ended June 30, 2019 and 2018, the Company incurred net losses from continuing operations of approximately $2.4 million and $5.7 million, respectively, and used cash in continuing operations of approximately $3.0 million and $5.5 million, respectively. The Company had an accumulated deficit of approximately $232 million and $229 million as of June 30, 2019 and December 31, 2018, respectively. To date, the Company’s operations have been principally financed by proceeds received from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operating activities. The Company’s continuation as a going concern is dependent upon its ability to increase sales and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operating activities or obtain additional financing is uncertain.   The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of the Company’s silicon nitride material are not well known, and the Company believes that the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications.   The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering. In March 2018, the Company closed on gross proceeds of $1.4 million, before payment of placement agent fees and costs on a warrant reprice and exercise transaction. Additionally, on May 14, 2018, the Company closed on a public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of our common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $1.6 million, (ii) the termination by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) June 4, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the three months ended June 30, 2019 the Company raised $0.397 million, net of fees through the issuance of 144,415 shares of common stock under the Distribution Agreement with Maxim. The Company is eligible to raise an additional $1.2 million under this offering. In addition, the Company converted 3,337 shares of preferred stock into 983,528 shares of common stock. The Company is engaged in discussions with investment and banking firms to examine financing alternatives, including options for a public offering of the Company’s preferred or common stock. On October 1, 2018, the Company sold the retail spine business. This sale will continue to provide cash flows from July 2019 totaling $1.4 million over the next ten months and $3.5 million for the following eighteen months. The buyer also assumed the Company’s $2.5 million related party note payable.   Although the Company is seeking to obtain additional equity and/or debt financing, such funding is not assured and may not be available to the Company on favorable or acceptable terms and may involve significant restrictive covenants. Any additional equity financing is also not assured and, if available to the Company, will most likely be dilutive to its current stockholders. If the Company is not able to obtain additional debt or equity financing on a timely basis, the impact on the Company will be material and adverse.   These uncertainties create substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Significant Accounting Policies   Except as explained below, no material changes were made to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Accounting Pronouncements Adopted During the Quarter Ended June 30, 2019   In August 2016, the FASB updated accounting guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Under prior U.S. GAAP, there was no specific guidance on the eight cash flow classification issues aforementioned. The Company adopted the new guidance effective January 1, 2019. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption.   In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The Company adopted the new guidance effective January 1, 2019 (see Note 13), using the modified retrospective approach. Adoption of the new guidance resulted in the Company being required to record an additional operating lease right-of-use asset totaling approximately $0.659 million and liability totaling approximately $0.946 million (with $0.659 million incremental to adoption of the new guidance) on the date of adoption. Subsequent to the initial adoption of the new standard the Company amended the lease (see Note 13). The standard did not materially impact the consolidated net loss and had no impact on cash flows.   In May 2014, in addition to several amendments issued during 2016, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The Company adopted the new guidance effective January 1, 2019. The core principle of the new guidance is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates are often required within the revenue recognition process than were required under prior U.S. GAAP. The Company has one primary customer (see Note 12) and related contract that has one performance obligation to which revenue is allocated. Revenue under this contract is recognized when the product is shipped to the customer. The Company generally bills its customer upon shipment of the product and invoices are generally due within 30 days. The Company does provide certain rights of return, which historically have not been significant. The Company does not anticipate incurring significant incremental costs to obtain contracts with future customers. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption.

New Accounting Pronouncements Not Yet Adopted   The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

Intangible assets consisted of the following (in thousands):   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Trademarks</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">50</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">44</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">46</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

This agreement extends for a total of 24 months, ending on September 30, 2020.

6000000

4300000

500 27139 1000 1633000 1000 1633000 9000 9000 565000 565000 1600000 1600000 0.0425

144415

400000

1100000

EX-101.SCH 6 sint-20190630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Basic and Diluted Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note Receivable link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Basic and Diluted Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Basic and Diluted Net Loss Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Inventories (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Inventories - Schedule of Components of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Fair Value Measurements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Note Receivable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Discontinued Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Leases - Schedule of Operating Lease Future Minimum Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sint-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 sint-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 sint-20190630_lab.xml XBRL LABEL FILE Indefinite Lived Intangible Assets By Major Class [Axis] Trademarks [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Measurement Frequency [Axis] Fair Value, Measurements, Recurring [Member] Equity Components [Axis] Common Stock Warrants [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Related Party [Axis] North Stadium Investments, LLC [Member] Hercules Technology Capital, Inc. [Member] Agreement [Axis] Loan and Security Agreement [Member] Valuation Approach and Technique [Axis] Monte Carlo Simulation Valuation Model [Member] Warrants [Member] Black-Scholes-Merton Valuation Model [Member] Debt Instrument [Axis] L2 Capital Debt [Member] Hercules Term Loan [Member] Long-term Debt, Type [Axis] Senior Secured Convertible Promissory Notes One [Member] Senior Secured Convertible Promissory Notes Two [Member] Exchange Notes [Member] Award Date [Axis] Closing Date [Member] Preferred Stock [Member] Common Stock [Member] Convertible Preferred Stock and Warrants [Member] Sale of Stock [Axis] Public Offering [Member] Class of Stock [Axis] Series B Convertible Preferred Stock [Member] Liability Class [Axis] Measurement Input Type [Axis] Weighted-Average Expected Life [Member] MEF I, L.P. and Anson Investments [Member] Award Type [Axis] July 12, 2018 [Member] August 2018 Warrant Exercise [Member] Secondary Offering [Member] July 2018 Warrant Exercise [Member] Public Offering [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] July Through December of 2018 [Member] Legal Entity [Axis] Retail Spine Business [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Asset Purchase Agreement [Member] Receivable Type [Axis] Interest Note Receivable [Member] Short-term Debt, Type [Axis] Related Party Note Payable [Member] Series E Common Stock Purchase Warrant [Member] New Warrants [Member] Disposal Group Classification [Axis] Discontinued Operations, Spine Business [Member] Warrant Derivative [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Scenario [Axis] Next Ten Months [Member] Following Eighteen Months [Member] Weighted-Average Risk-Free Interest Rate [Member] Expected Dividend Yield [Member] Weighted-Average Expected Volatility [Member] May 2018 Warrant Exercise (July 2016 Warrants) [Member] Range [Axis] Minimum [Member] Maximum [Member] Equity Distribution Agreement [Member] ATM Equity Distribution Agreement [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Trade accounts receivable, net of allowance of $6 and $56, respectively Prepaid expenses and other current assets Inventories Notes receivable, current portion Total current assets Inventories, net Property and equipment, net Intangible assets, net Long-term note receivable, net of current portion Operating lease right-of-use-asset Other long-term assets Total assets Liabilities and stockholders' equity Current liabilities: Accounts payable Accrued liabilities Derivative liabilities, current portion Current portion of operating lease liability Other current liabilities Total current liabilities Operating lease liability, net of current portion Derivative liabilities, net of current portion Other long-term liabilities Total liabilities Commitments and contingencies Stockholders' equity: Convertible preferred stock, $0.01 par value, 130,000,000 shares authorized; 737 shares and 4,074 shares issued and outstanding at June 30, 2019 and December 31, 2018. Common stock, $0.01 par value, 250,000,000 shares authorized; 1,854,898 shares, and 726,455 shares issued and outstanding at June 30, 2019 and December 31, 2018. Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Allowance of trade accounts receivable Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Product revenue Costs of revenue Gross profit Operating expenses: Research and development General and administrative Sales and marketing Total operating expenses Loss from operations Other income (expenses): Interest expense Interest income Change in fair value of derivative liabilities Loss on extinguishment of debt Offering costs Loss on extinguishment of derivative liabilities Other income, net Total other income (expense), net Net loss from continuing operations before income taxes Provision for income taxes Loss from continuing operations Loss from discontinued operations Net loss Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock Net loss attributable to common stockholders Net loss per share - basic and diluted Basic - continuing operations Basic - discontinued operations Basic - deemed dividend and accretion of a discount on conversion of series B preferred stock Basic - attributable to common stockholders Diluted - continuing operations Diluted - discontinued operations Diluted - deemed dividend and accretion of a discount on conversion of series B preferred stock Diluted - attributable to common stockholders Weighted average common shares outstanding: Basic Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Common stock issued from exercise of warrants Common stock issued from exercise of warrants, shares Issuance of common stock in exchange for reduction in debt Issuance of common stock in exchange for reduction in debt, shares Issuance of preferred stock from offering, net of issuance costs Issuance of preferred stock from offering, net of issuance costs, shares Warrants issued in association with debt Loss on extinguishment of derivative liabilities Deemed dividend related to adjustment of the exercise price of warrants issued with debt Accretion of change in warrant exercise price Common stock issued due to conversion of preferred stock Common stock issued due to conversion of preferred stock, shares EX-101.PRE 10 sint-20190630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 12, 2019
Document And Entity Information
Entity Registrant Name	Sintx Technologies, Inc.
Entity Central Index Key	0001269026
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,957,930
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 3,192	$ 5,447
Trade accounts receivable, net of allowance of $6 and $56, respectively	173	263
Prepaid expenses and other current assets	234	171
Inventories	85	52
Notes receivable, current portion	1,399	1,084
Total current assets	5,083	7,017
Inventories, net	596	624
Property and equipment, net	87	124
Intangible assets, net	44	46
Long-term note receivable, net of current portion	2,897	3,669
Operating lease right-of-use-asset	2,535
Other long-term assets	35	35
Total assets	11,277	11,515
Current liabilities:
Accounts payable	295	301
Accrued liabilities	813	838
Derivative liabilities, current portion	454	1,062
Current portion of operating lease liability	587	169
Other current liabilities	23	10
Total current liabilities	2,172	2,380
Operating lease liability, net of current portion	2,050
Derivative liabilities, net of current portion	502	504
Other long-term liabilities	113	232
Total liabilities	4,837	3,116
Commitments and contingencies
Stockholders' equity:
Convertible preferred stock, $0.01 par value, 130,000,000 shares authorized; 737 shares and 4,074 shares issued and outstanding at June 30, 2019 and December 31, 2018.
Common stock, $0.01 par value, 250,000,000 shares authorized; 1,854,898 shares, and 726,455 shares issued and outstanding at June 30, 2019 and December 31, 2018.	19	7
Additional paid-in capital	238,062	237,673
Accumulated deficit	(231,641)	(229,281)
Total stockholders' equity	6,440	8,399
Total liabilities and stockholders' equity	$ 11,277	$ 11,515

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Allowance of trade accounts receivable	$ 6	$ 56
Convertible preferred stock, par value	$ 0.01	$ 0.01
Convertible preferred stock, shares authorized	130,000,000	130,000,000
Convertible preferred stock, shares issued	737	4,074
Convertible preferred stock, shares outstanding	737	4,074
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	1,854,898	726,455
Common stock, shares outstanding	1,854,898	726,455

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Product revenue	$ 167		$ 264
Costs of revenue	133		212
Gross profit	34		52
Operating expenses:
Research and development	836	956	1,554	1,833
General and administrative	615	935	1,586	2,242
Sales and marketing	105	11	164	58
Total operating expenses	1,556	1,902	3,304	4,133
Loss from operations	(1,522)	(1,902)	(3,252)	(4,133)
Other income (expenses):
Interest expense	(2)	(809)	(2)	(1,284)
Interest income	115		237
Change in fair value of derivative liabilities	631	1,209	610	2,020
Loss on extinguishment of debt				(340)
Offering costs		(682)		(682)
Loss on extinguishment of derivative liabilities				(1,252)
Other income, net	48	3	48	5
Total other income (expense), net	792	(279)	893	(1,533)
Net loss from continuing operations before income taxes	(730)	(2,181)	(2,359)	(5,666)
Provision for income taxes
Loss from continuing operations	(730)	(2,181)	(2,359)	(5,666)
Loss from discontinued operations		(131)		(44)
Net loss	(730)	(2,312)	(2,359)	(5,710)
Deemed dividend related to the beneficial conversion feature and accretion of a discount on series B preferred stock	(2,358)	(7,334)	(2,358)	(7,334)
Net loss attributable to common stockholders	$ (3,088)	$ (9,646)	$ (4,717)	$ (13,044)
Net loss per share - basic and diluted
Basic - continuing operations	$ (0.78)	$ (11.19)	$ (2.84)	$ (36.66)
Basic - discontinued operations		(0.67)		(0.28)
Basic - deemed dividend and accretion of a discount on conversion of series B preferred stock	(2.53)	(37.62)	(2.84)	(47.46)
Basic - attributable to common stockholders	(3.31)	(49.48)	(5.68)	(84.40)
Diluted - continuing operations	(1.46)	(12.06)	(3.58)	(39.01)
Diluted - discontinued operations		(0.42)		(0.28)
Diluted - deemed dividend and accretion of a discount on conversion of series B preferred stock	(2.53)	(23.33)	(2.84)	(47.46)
Diluted - attributable to common stockholders	$ (3.99)	$ (35.81)	$ (6.42)	$ (86.75)
Weighted average common shares outstanding:
Basic	931,859	194,933	829,724	154,545
Diluted	931,859	314,354	829,724	154,545

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017		$ 1	$ 226,070	$ (220,629)	$ 5,442
Balance, shares at Dec. 31, 2017		100,935
Common stock issued from exercise of warrants			1,633		1,633
Common stock issued from exercise of warrants, shares		27,139
Issuance of common stock in exchange for reduction in debt			1,453		1,453
Issuance of common stock in exchange for reduction in debt, shares		19,348
Issuance of preferred stock from offering, net of issuance costs			6,754		6,754
Issuance of preferred stock from offering, net of issuance costs, shares	15
Warrants issued in association with debt			98		98
Loss on extinguishment of derivative liabilities			1,040		1,040
Deemed dividend related to adjustment of the exercise price of warrants issued with debt			(9)		(9)
Accretion of change in warrant exercise price			9		9
Common stock issued due to conversion of preferred stock		$ 1	(1)
Common stock issued due to conversion of preferred stock, shares	(4)	102,886
Accretion of convertible preferred stock discount			7,334		7,334
Deemed dividend related to the issuance of preferred stock			(7,334)		(7,334)
Extinguishment of derivative liabilities			565		565
Stock-based compensation			34		34
Net loss				(5,711)	(5,710)
Balance at Jun. 30, 2018		$ 2	237,646	(226,339)	11,309
Balance, shares at Jun. 30, 2018	11	250,308
Balance at Dec. 31, 2018		$ 7	237,673	(229,281)	8,399
Balance, shares at Dec. 31, 2018	4,074	726,455
Common stock issued from exercise of warrants			1		1
Common stock issued from exercise of warrants, shares		500
Issuance of common stock in exchange for reduction in debt
Common stock issued due to conversion of preferred stock		$ 10	(10)
Common stock issued due to conversion of preferred stock, shares	(3,337)	983,528
Stock-based compensation			1		1
Common Stock Issued for Cash		$ 1	396		397
Common Stock Issued for Cash, shares		144,415
Removal of derivative liability upon Exercise of warrant			1		1
Net loss				(2,359)	(2,359)
Balance at Jun. 30, 2019		$ 18	$ 238,062	$ (231,640)	$ 6,440
Balance, shares at Jun. 30, 2019	737	1,854,898

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flow from operating activities
Net loss from continuing operations	$ (2,359)	$ (5,666)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	52	53
Non-cash lease expense	171	(99)
Amortization of intangible assets	2
Amortization of lease incentive for tenant improvements		28
Non-cash interest income	(237)
Non-cash interest expense		812
Loss on extinguishment of debt		340
Stock based compensation	1	34
Change in fair value of derivative liabilities	(610)	(2,020)
Loss on extinguishment of derivative liabilities		1,252
Loss on disposal of equipment		51
Bad debt expense	9
Changes in operating assets and liabilities:
Trade accounts receivable	79
Prepaid expenses and other current assets	(63)	(76)
Inventories	(5)
Accounts payable and accrued liabilities	(19)	(241)
Net cash used in operating activities - continuing operations	(2,979)	(5,532)
Net cash used in operating activities - discontinued operations		(402)
Net cash used in operating activities	(2,979)	(5,934)
Cash flows from investing activities
Purchase of property and equipment	(15)
Proceeds from notes receivable, net of imputed interest	695
Purchase of intangible asset		(50)
Net cash provided by (used in) investing activities - continuing operations	680	(50)
Net cash used in investing activities - discontinued operations		(107)
Net cash used in investing activities	680	(157)
Cash flows from financing activities
Proceeds from issuance of stock in connection with exercise of warrants, net of issuance costs	1	1,633
Proceeds from issuance of common stock, net of fees ($131)	397
Proceeds from issuance of preferred stock, net of issuance costs ($668)		6,754
Proceeds from issuance of warrant derivative liabilities, net of issuance costs ($682)		7,577
Payments on operating lease liability	(354)
Proceeds from issuance of debt		705
Payments on debt		(2,282)
Net cash provided by (used in) financing activities	44	14,387
Net increase (decrease) in cash and cash equivalents	(2,255)	8,296
Cash and cash equivalents at beginning of period	5,447	539
Cash and cash equivalents at end of period	3,192	8,835
Noncash investing and financing activities
Right-of-use assets and assumption of operating lease liability	2,704
Reduction of derivative liability due to exercise of warrants	1
Hercules and MEF I, LP/Anson Investments Debt Exchange		2,265
Issuance of common stock in exchange for reduction in debt		1,453
Extinguishment of derivative liabilities through exercise of warrants		565
Warrants issued in association with debt		98
Supplemental cash flow information
Cash paid for interest	$ 2	$ 337

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Common Stock [Member]
Fee & issuance costs	$ 131
Preferred Stock [Member]
Fee & issuance costs		$ 668
Warrant Derivative [Member]
Fee & issuance costs		$ 682

XML 18 R8.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Organization

As further explained in Note 14, the Company effected a 1 for 30 reverse stock split of the Company’s common stock on July 26, 2019.

Basis of Presentation

Use of Estimates

Liquidity and Capital Resources

Significant Accounting Policies

Accounting Pronouncements Adopted During the Quarter Ended June 30, 2019

New Accounting Pronouncements Not Yet Adopted

XML 19 R9.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Basic and Diluted Net Loss Per Common Share

2. Basic and Diluted Net Loss per Common Share

Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(730	)	$	(632	)	$	(1,362	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(3,088	)	$	(632	)	$	(3,720	)

Denominator:
Number of shares used in per common share calculations:		931,859			-			931,859

Net loss per common share:
Loss from continuing operations	$	(0.78	)	$	-		$	(1.46	)
Deemed dividend and accretion of a discount		(2.53	)		-			(2.53	)
Net loss attributable to common stockholders	$	(3.31	)	$	-		$	(3.99	)

Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(2,359	)	$	(609	)	$	(2,968	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(4,717	)	$	(609	)	$	(5,326	)

Denominator:
Number of shares used in per common share calculations:		829,724			-			829,724

Net loss per common share:
Loss from continuing operations	$	(2.84	)	$	-		$	(3.58	)
Deemed dividend and accretion of a discount		(2.84	)		-			(2.84	)
Net loss attributable to common stockholders	$	(5.68	)	$	-		$	(6.42	)

Below are basic and diluted loss per share data for the three months ended June 30, 2018, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(2,181	)	$	(1,610	)	$	(3,791	)
Income from discontinued operations		(131	)		-			(131	)
Deemed dividend and accretion of a discount		(7,334	)		-			(7,334	)
Net loss attributable to common stockholders	$	(9,646	)	$	(1,610	)	$	(11,256	)

Denominator:
Number of shares used in per common share calculations:		194,933			119,421			314,354

Net loss per common share:
Loss from continuing operations	$	(11.19	)	$	-		$	(12.06	)
Loss from discontinued operations		(0.67	)		-			(0.42	)
Deemed dividend and accretion of a discount		(37.62	)		-			(23.33	)
Net loss attributable to common stockholders	$	(49.48	)	$	-		$	(35.81	)

Below are basic and diluted loss per share data for the six months ended June 30, 2018, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(5,666	)	$	(362	)	$	(6,028	)
Income from discontinued operations		(44	)		-			(44	)
Deemed dividend and accretion of a discount		(7,334	)		-			(7,334	)
Net loss attributable to common stockholders	$	(13,044	)	$	(362	)	$	(13,406	)

Denominator:
Number of shares used in per common share calculations:		154,545			-			154,545

Net loss per common share:
Loss from continuing operations	$	(36.66	)	$	-		$	(39.01	)
Loss from discontinued operations		(0.28	)		-			(0.28	)
Deemed dividend and accretion of a discount		(47.46	)		-			(47.46	)
Net loss attributable to common stockholders	$	(84.40	)	$	-		$	(86.75	)

XML 20 R10.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2019

Inventory Disclosure [Abstract]

Inventories

3. Inventories

Inventories consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Raw materials	$	596	$	624
Intermediate goods		9		-
WIP		76		47
Finished goods		-		5
	$	681	$	676

XML 21 R11.htm IDEA: XBRL DOCUMENT

Intangible Assets

6 Months Ended

Jun. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

4. Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Trademarks	$	50		$	50
Less: accumulated amortization		(6	)		(4	)
	$	44		$	46

XML 22 R12.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

5. Fair Value Measurements

Financial Instruments Measured and Recorded at Fair Value on a Recurring Basis

	Level 1 -	quoted market prices for identical assets or liabilities in active markets.

	Level 2 -	observable prices that are based on inputs not quoted on active markets but corroborated by market data.

	Level 3 -	unobservable inputs reflecting management’s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

	Fair Value Measurements as of June 30, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	956	$	956

	Fair Value Measurements as of December 31, 2018
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,566	$	1,566

The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended June 30, 2019 and 2018.

	Common Stock Warrants
Balance at December 31, 2017	$	(1,357	)
Issuances of warrants classified as derivatives		(7,577	)
Change in fair value		2,020
Exercise of warrants		565
Other, net		(212	)
Balance at June 30, 2018	$	(6,561	)

Balance at December 31, 2018	$	(1,566	)
Change in fair value		610
Balance at June 30, 2019	$	(956	)

Common Stock Warrants

The Company has issued certain warrants to purchase shares of common stock, which are considered derivative liabilities because they have registration rights which could require a cash settlement and are re-measured to fair value at each reporting period in accordance with accounting guidance. At June 30, 2019 and December 31, 2018, approximately $0.9 million of the derivative liability was calculated using the Black-Scholes-Merton valuation model. At June 30, 2019 and December 31, 2018, no significant amount of the derivative liability was calculated using the Monte Carlo Simulation valuation model.

The assumptions used in estimating the common stock warrant liability using the Black-Scholes-Merton valuation model as of June 30, 2019 and December 31, 2018 were as follows:

	June 30, 2019			December 31, 2018
Weighted-average risk-free interest rate		2.23	%		2.51	%
Weighted-average expected life (in years)		4.1			0.9
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		68	%		157	%

The assumptions used in estimating the common stock warrant liability using the Monte Carlo Simulation valuation model at June 30, 2019 and December 31, 2018 were as follows:

	June 30, 2019			December 31, 2018
Weighted-average risk-free interest rate		1.72	%		2.46	%
Weighted-average expected life (in years)		2.4			3.1
Expected dividend yield		-	%		-	%
Weighted average expected volatility		64	%		68	%

Other Financial Instruments

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Accrued Liabilities

6. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Payroll and related expense	$	413	$	388
Resterilization and repackaging costs		344		344
Other		56		106
	$	813	$	838

XML 24 R14.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Debt

7. Debt

L2 Capital Debt

Hercules and MEF I, LP/Anson Investments Debt Exchange

On May 14, 2018, the Company closed on an underwritten public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15.0 million. Part of the proceeds from this offering were used to pay off the outstanding debt with MEF I, L.P and Anson Investments. The total payoff was $1.6 million, with $1.4 million in principal and $0.2 million in interest.

North Stadium Term Loan – Related Party

Hercules Term Loan

XML 25 R15.htm IDEA: XBRL DOCUMENT

Equity

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Equity

8. Equity

Preferred Stock Conversion

From July through December of 2018, Series B Convertible Preferred shareholders of the Company converted 10,926 shares of Series B Convertible Preferred Stock into 569,966 shares of common stock.

During June 2019, Series B Convertible Preferred shareholders of the Company converted 3,337 shares of Series B Convertible Preferred Stock into 983,528 shares of common stock.

August 2018 Warrant Exercise

July 2018 Warrant Exercise

May 2018 Warrant Exercise (July 2016 Warrants)

May 2018 Unit Offering

Warrant Reprice March 2018

June 2019 ATM Stock Offerings

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

A summary of the Company’s outstanding stock option activity for the six months ended June 30, 2019 is as follows:

	Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Intrinsic Value
As of December 31, 2018		377	$	7,653		6.0	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
As of June 30, 2019		377	$	7,653		5.8	$	-
Exercisable as of June 30, 2019		371	$	7,551		6.3	$	-
Expected to vest as of June 30, 2019		377	$	7,653		5.5	$	-

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note Receivable

6 Months Ended

Jun. 30, 2019

Receivables [Abstract]

Note Receivable

11. Note Receivable

XML 29 R19.htm IDEA: XBRL DOCUMENT

Discontinued Operations

6 Months Ended

Jun. 30, 2019

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

12. Discontinued Operations

Operating results related to discontinued operations consisted of the following for the six months ended June 30, 2018:

	Six Months Ended
	June 30, 2018
Product revenue	$	4,330
Costs of revenue		1,045
Gross profit		3,285
Operating expenses:
Research and development		717
General and administrative		348
Sales and marketing		2,264
Total operating expenses		3,329
Loss from discontinued operations	$	(44)

XML 30 R20.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases

13. Leases

Operating lease future minimum payments together with the present values as of June 30, 2019, are summarized as follows:

	June 30, 2019
2019	$	490
2020		494
2021		509
2022		525
2023		540
Thereafter		556
Total future minimum lease payments		3,114
Less amounts representing interests		(477	)
Present value of lease liability		2,637

Current-portion of operating lease liability		587
Long-term portion operating lease liability	$	2,050

XML 31 R21.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

Subsequent Events

14. Subsequent Events

Reverse Stock Split

XML 32 R22.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Organization	Organization SINTX Technologies, Inc. (“SINTX” or “the Company”) (previously known as Amedica Corporation) was incorporated in the state of Delaware on December 10, 1996. SINTX is an OEM ceramics company that develops and commercializes silicon nitride for medical and non-medical applications. The Company believes it is the first and only manufacturer to use silicon nitride in medical applications. The Company acquired US Spine, Inc. (“US Spine”), a Delaware spinal products corporation with operations in Florida, on September 20, 2010. The Company’s products are primarily sold in the United States. As further explained in Note 12, On October 1, 2018, the Company completed the sale of its retail spine business to CTL Medical, a Dallas, Texas-based privately held medical device manufacturer. As a result of the sale, CTL Medical is now the exclusive owner of SINTX’s portfolio of metal and silicon nitride spine products, which are presently sold under the brand names of Taurus, Preference, and Valeo, with access to future silicon nitride spine technologies. Manufacturing, R&D, and all intellectual property related to the core, non-spine, biomaterial technology of silicon nitride remains with the Company. The Company will serve as CTL’s exclusive OEM provider of silicon nitride products. On October 30, 2018, the Company amended its Certificate of Incorporation with the State of Delaware to change its corporate name to SINTX Technologies, Inc. in order to better reflect its focus on silicon nitride science and technologies and pipeline of silicon nitride-based products in various biomedical applications. The Company also changed its trading symbol on the NASDAQ Capital Market to “SINT”. The Company also changed the name of its wholly owned subsidiary US Spine, Inc. to “ST Sub, Inc.” The previous name, Amedica, has transferred to CTL Medical, which is now CTL-Amedica. The Company’s new corporate brand reflects both the Company’s core competence in the science and production of silicon nitride ceramics, as well as encouraging prospects for the future, as an OEM supplier of spine implants to CTL-Amedica, and several opportunities outside of spine. The Company will focus on developing silicon nitride in terms of product design, and future biomaterial formulations, for a variety of OEM customers. As further explained in Note 14, the Company effected a 1 for 30 reverse stock split of the Company’s common stock on July 26, 2019.
Basis of Presentation	Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company and its wholly owned subsidiary, ST Sub, Inc. All material intercompany transactions and balances have been eliminated in consolidation. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States, so long as the statements are not misleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 11, 2019. The results of operations for the six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019. The Company’s significant accounting policies are set forth in Note 1 to the consolidated financial statements in its Annual Report on Form 10-K for the year ended December 31, 2018.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the periods then ended. Actual results could differ from those estimates. The most significant estimates relate to inventory, long-lived and intangible assets and the liability for preferred stock and common stock warrants.
Liquidity and Capital Resources	Liquidity and Capital Resources The condensed consolidated financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern within one year from the date of issuance of these condensed consolidated financial statements. For the six months ended June 30, 2019 and 2018, the Company incurred net losses from continuing operations of approximately $2.4 million and $5.7 million, respectively, and used cash in continuing operations of approximately $3.0 million and $5.5 million, respectively. The Company had an accumulated deficit of approximately $232 million and $229 million as of June 30, 2019 and December 31, 2018, respectively. To date, the Company’s operations have been principally financed by proceeds received from the issuance of preferred and common stock, convertible debt and bank debt and, to a lesser extent, cash generated from product sales. It is anticipated that the Company will continue to generate operating losses and use cash in operating activities. The Company’s continuation as a going concern is dependent upon its ability to increase sales and/or raise additional funds through the capital markets. Whether and when the Company can attain profitability and positive cash flows from operating activities or obtain additional financing is uncertain. The Company is actively generating additional scientific and clinical data to have it published in leading industry publications. The unique features of the Company’s silicon nitride material are not well known, and the Company believes that the publication of such data would help sales efforts as the Company approaches new prospects. The Company is also making additional changes to the sales strategy, including a focus on revenue growth by expanding the use of silicon nitride in other areas outside of spinal fusion applications. The Company has common stock that is publicly traded and has been able to successfully raise capital when needed since the date of the Company’s initial public offering. In March 2018, the Company closed on gross proceeds of $1.4 million, before payment of placement agent fees and costs on a warrant reprice and exercise transaction. Additionally, on May 14, 2018, the Company closed on a public offering of units, consisting of convertible preferred stock and warrants, for gross proceeds of $15 million, which excludes underwriting discounts and commissions and offering expenses payable by the Company. On June 4, 2019, the Company entered into an Equity Distribution Agreement, (the “Distribution Agreement”), with Maxim Group LLC (“Maxim”), pursuant to which the Company may sell from time to time, shares of our common stock, having an aggregate offering price of up to $1.6 million through Maxim, as agent (the “ATM Offering”). Subject to the terms and conditions of the Distribution Agreement, Maxim will use its commercially reasonable efforts to sell the shares from time to time, based on the Company’s instructions. The Company has no obligation to sell any of the shares and may at any time suspend offers under the Distribution Agreement. The Offering will terminate upon the earlier of (i) the sale of Shares having an aggregate offering price of $1.6 million, (ii) the termination by either Maxim or the Company upon the provision of fifteen (15) days written notice, or (iii) June 4, 2020. The Company agrees to pay Maxim a transaction fee at a fixed rate of 4.25% of the gross sales price of shares sold under the Distribution Agreement and agreed to provide indemnification and contribution to Maxim with respect to certain liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended. During the three months ended June 30, 2019 the Company raised $0.397 million, net of fees through the issuance of 144,415 shares of common stock under the Distribution Agreement with Maxim. The Company is eligible to raise an additional $1.2 million under this offering. In addition, the Company converted 3,337 shares of preferred stock into 983,528 shares of common stock. The Company is engaged in discussions with investment and banking firms to examine financing alternatives, including options for a public offering of the Company’s preferred or common stock. On October 1, 2018, the Company sold the retail spine business. This sale will continue to provide cash flows from July 2019 totaling $1.4 million over the next ten months and $3.5 million for the following eighteen months. The buyer also assumed the Company’s $2.5 million related party note payable. Although the Company is seeking to obtain additional equity and/or debt financing, such funding is not assured and may not be available to the Company on favorable or acceptable terms and may involve significant restrictive covenants. Any additional equity financing is also not assured and, if available to the Company, will most likely be dilutive to its current stockholders. If the Company is not able to obtain additional debt or equity financing on a timely basis, the impact on the Company will be material and adverse. These uncertainties create substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
Significant Accounting Policies	Significant Accounting Policies Except as explained below, no material changes were made to the Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.
Accounting Pronouncements Adopted During the Quarter Ended March 31, 2019	Accounting Pronouncements Adopted During the Quarter Ended June 30, 2019 In August 2016, the FASB updated accounting guidance on the following eight specific cash flow classification issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. Under prior U.S. GAAP, there was no specific guidance on the eight cash flow classification issues aforementioned. The Company adopted the new guidance effective January 1, 2019. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption. In February 2016, the FASB updated the accounting guidance related to leases as part of a joint project with the International Accounting Standards Board (“IASB”) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The Company adopted the new guidance effective January 1, 2019 (see Note 13), using the modified retrospective approach. Adoption of the new guidance resulted in the Company being required to record an additional operating lease right-of-use asset totaling approximately $0.659 million and liability totaling approximately $0.946 million (with $0.659 million incremental to adoption of the new guidance) on the date of adoption. Subsequent to the initial adoption of the new standard the Company amended the lease (see Note 13). The standard did not materially impact the consolidated net loss and had no impact on cash flows. In May 2014, in addition to several amendments issued during 2016, the FASB updated the accounting guidance related to revenue from contracts with customers, which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The Company adopted the new guidance effective January 1, 2019. The core principle of the new guidance is that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. The standard defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates are often required within the revenue recognition process than were required under prior U.S. GAAP. The Company has one primary customer (see Note 12) and related contract that has one performance obligation to which revenue is allocated. Revenue under this contract is recognized when the product is shipped to the customer. The Company generally bills its customer upon shipment of the product and invoices are generally due within 30 days. The Company does provide certain rights of return, which historically have not been significant. The Company does not anticipate incurring significant incremental costs to obtain contracts with future customers. The guidance in this standard did not have a material impact on the financial statements of the Company upon adoption.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its financial statements.

XML 33 R23.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share (Tables)

6 Months Ended

Jun. 30, 2019

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Loss Per Share

Below are basic and diluted loss per share data for the three months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(730	)	$	(632	)	$	(1,362	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(3,088	)	$	(632	)	$	(3,720	)

Denominator:
Number of shares used in per common share calculations:		931,859			-			931,859

Net loss per common share:
Loss from continuing operations	$	(0.78	)	$	-		$	(1.46	)
Deemed dividend and accretion of a discount		(2.53	)		-			(2.53	)
Net loss attributable to common stockholders	$	(3.31	)	$	-		$	(3.99	)

Below are basic and diluted loss per share data for the six months ended June 30, 2019, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(2,359	)	$	(609	)	$	(2,968	)
Deemed dividend and accretion of a discount		(2,358	)		-			(2,358	)
Net loss attributable to common stockholders	$	(4,717	)	$	(609	)	$	(5,326	)

Denominator:
Number of shares used in per common share calculations:		829,724			-			829,724

Net loss per common share:
Loss from continuing operations	$	(2.84	)	$	-		$	(3.58	)
Deemed dividend and accretion of a discount		(2.84	)		-			(2.84	)
Net loss attributable to common stockholders	$	(5.68	)	$	-		$	(6.42	)

Below are basic and diluted loss per share data for the three months ended June 30, 2018, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(2,181	)	$	(1,610	)	$	(3,791	)
Income from discontinued operations		(131	)		-			(131	)
Deemed dividend and accretion of a discount		(7,334	)		-			(7,334	)
Net loss attributable to common stockholders	$	(9,646	)	$	(1,610	)	$	(11,256	)

Denominator:
Number of shares used in per common share calculations:		194,933			119,421			314,354

Net loss per common share:
Loss from continuing operations	$	(11.19	)	$	-		$	(12.06	)
Loss from discontinued operations		(0.67	)		-			(0.42	)
Deemed dividend and accretion of a discount		(37.62	)		-			(23.33	)
Net loss attributable to common stockholders	$	(49.48	)	$	-		$	(35.81	)

Below are basic and diluted loss per share data for the six months ended June 30, 2018, which are in thousands except for share and per share data:

	Basic Calculation			Effect of Dilutive Warrant Securities			Diluted Calculation
Numerator:
Loss from continuing operations	$	(5,666	)	$	(362	)	$	(6,028	)
Income from discontinued operations		(44	)		-			(44	)
Deemed dividend and accretion of a discount		(7,334	)		-			(7,334	)
Net loss attributable to common stockholders	$	(13,044	)	$	(362	)	$	(13,406	)

Denominator:
Number of shares used in per common share calculations:		154,545			-			154,545

Net loss per common share:
Loss from continuing operations	$	(36.66	)	$	-		$	(39.01	)
Loss from discontinued operations		(0.28	)		-			(0.28	)
Deemed dividend and accretion of a discount		(47.46	)		-			(47.46	)
Net loss attributable to common stockholders	$	(84.40	)	$	-		$	(86.75	)

XML 34 R24.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Jun. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Components of Inventory

Inventories consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Raw materials	$	596	$	624
Intermediate goods		9		-
WIP		76		47
Finished goods		-		5
	$	681	$	676

XML 35 R25.htm IDEA: XBRL DOCUMENT

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following (in thousands):

	June 30, 2019			December 31, 2018
Trademarks	$	50		$	50
Less: accumulated amortization		(6	)		(4	)
	$	44		$	46

XML 36 R26.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level Within Fair Value Hierarchy

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of June 30, 2019 and December 31, 2018:

	Fair Value Measurements as of June 30, 2019
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	956	$	956

	Fair Value Measurements as of December 31, 2018
Description	Level 1		Level 2		Level 3		Total
Derivative liability
Common stock warrants	$	-	$	-	$	1,566	$	1,566

Schedule of Fair Value Measurement Hierarchy of Derivative Liability

The Company did not have any transfers of assets and liabilities between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended June 30, 2019 and 2018.

	Common Stock Warrants
Balance at December 31, 2017	$	(1,357	)
Issuances of warrants classified as derivatives		(7,577	)
Change in fair value		2,020
Exercise of warrants		565
Other, net		(212	)
Balance at June 30, 2018	$	(6,561	)

Balance at December 31, 2018	$	(1,566	)
Change in fair value		610
Balance at June 30, 2019	$	(956	)

Black-Scholes-Merton Valuation Model [Member]

Schedule of Assumptions Used in Estimating Fair Value

The assumptions used in estimating the common stock warrant liability using the Black-Scholes-Merton valuation model as of June 30, 2019 and December 31, 2018 were as follows:

	June 30, 2019			December 31, 2018
Weighted-average risk-free interest rate		2.23	%		2.51	%
Weighted-average expected life (in years)		4.1			0.9
Expected dividend yield		-	%		-	%
Weighted-average expected volatility		68	%		157	%

Monte Carlo Simulation Valuation Model [Member]

Schedule of Assumptions Used in Estimating Fair Value

The assumptions used in estimating the common stock warrant liability using the Monte Carlo Simulation valuation model at June 30, 2019 and December 31, 2018 were as follows:

	June 30, 2019			December 31, 2018
Weighted-average risk-free interest rate		1.72	%		2.46	%
Weighted-average expected life (in years)		2.4			3.1
Expected dividend yield		-	%		-	%
Weighted average expected volatility		64	%		68	%

XML 37 R27.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2019

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2019		December 31, 2018
Payroll and related expense	$	413	$	388
Resterilization and repackaging costs		344		344
Other		56		106
	$	813	$	838

XML 38 R28.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Share-based Payment Arrangement [Abstract]

Summary of Stock Option Activity

A summary of the Company’s outstanding stock option activity for the six months ended June 30, 2019 is as follows:

	Options		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (Years)		Intrinsic Value
As of December 31, 2018		377	$	7,653		6.0	$	-
Granted		-		-		-		-
Exercised		-		-		-		-
Forfeited		-		-		-		-
Expired		-		-		-		-
As of June 30, 2019		377	$	7,653		5.8	$	-
Exercisable as of June 30, 2019		371	$	7,551		6.3	$	-
Expected to vest as of June 30, 2019		377	$	7,653		5.5	$	-

XML 39 R29.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

6 Months Ended

Jun. 30, 2019

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Operating results related to discontinued operations consisted of the following for the six months ended June 30, 2018:

	Six Months Ended
	June 30, 2018
Product revenue	$	4,330
Costs of revenue		1,045
Gross profit		3,285
Operating expenses:
Research and development		717
General and administrative		348
Sales and marketing		2,264
Total operating expenses		3,329
Loss from discontinued operations	$	(44)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

XML 40 R30.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule of Operating Lease Future Minimum Payments

Operating lease future minimum payments together with the present values as of June 30, 2019, are summarized as follows:

	June 30, 2019
2019	$	490
2020		494
2021		509
2022		525
2023		540
Thereafter		556
Total future minimum lease payments		3,114
Less amounts representing interests		(477	)
Present value of lease liability		2,637

Current-portion of operating lease liability		587
Long-term portion operating lease liability	$	2,050

XML 41 R31.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands						1 Months Ended		3 Months Ended		6 Months Ended
	Jul. 26, 2019	Jun. 04, 2019	Jan. 02, 2019	Oct. 02, 2018	May 14, 2018	Jul. 31, 2019	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Loss from continuing operations								$ (730)	$ (2,181)	$ (2,359)	$ (5,666)
Net cash used in operating activities										(2,979)	(5,532)
Accumulated deficit								(231,641)		(231,641)		$ (229,281)
Proceeds from issuance of private placement							$ 1,400
Proceeds from issuance of public offering					$ 15,000
Common stock issued for cash								$ 397		397
Common stock issued for cash, shares								144,415
Operating lease asset			$ 659					$ 2,535		2,535
Operating lease liability			946					$ 2,637		2,637
Right-of-use assets and assumption of operating lease liability			$ 659							2,704
Retail Spine Business [Member]
Related party note payable assumed amount				$ 2,500
Preferred Stock [Member]
Common stock issued for cash
Common stock issued for cash, shares
Issuance of common stock due to conversion of preferred stock, shares								3,337		(3,337)	(4)
Common Stock [Member]
Common stock issued for cash										$ 1
Common stock issued for cash, shares										144,415
Issuance of common stock due to conversion of preferred stock, shares								983,528		983,528	102,886
Equity Distribution Agreement [Member]
Percentage of maximum transaction fee		4.25%
Equity Distribution Agreement [Member] \| Maximum [Member]
Common stock offering price		$ 1,600
Subsequent Event [Member]
Reverse stock split, description	1 for 30 reverse stock split
Subsequent Event [Member] \| Retail Spine Business [Member] \| Next Ten Months [Member]
Proceeds from sales of business						$ 1,400
Subsequent Event [Member] \| Retail Spine Business [Member] \| Following Eighteen Months [Member]
Proceeds from sales of business						$ 3,500

XML 42 R32.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Potentially dilutive securities	600,000	700,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Loss from continuing operations, basic calculation	$ (730)	$ (2,181)	$ (2,359)	$ (5,666)
Income from discontinued operations		(131)		(44)
Deemed dividend and accretion of a discount, basic calculation	(2,358)	(7,334)	(2,358)	(7,334)
Net loss attributable to common stockholders, basic calculation	(3,088)	(9,646)	(4,717)	(13,044)
Loss from continuing operations, effect of dilutive warrant securities	(632)	(1,610)	(609)	(362)
Net loss attributable to common stockholders, effect of dilutive warrant securities	(632)	(1,610)	(609)	(362)
Loss from continuing operations, diluted calculation	(1,362)	(3,791)	(2,968)	(6,028)
Income from discontinued operations, diluted calculation		(131)		(44)
Deemed dividend and accretion of a discount, diluted calculation	(2,358)	(7,334)	(2,358)	(7,334)
Net loss attributable to common stockholders, diluted calculation	$ (3,720)	$ (11,256)	$ (5,326)	$ (13,406)
Number of shares used in per common share calculations, basic calculation	931,859	194,933	829,724	154,545
Number of shares used in per common share calculations, effect of dilutive warrant securities		119,421
Number of shares used in per common share calculations, diluted calculation	931,859	314,354	829,724	154,545
Loss from continuing operations, basic calculation	$ (0.78)	$ (11.19)	$ (2.84)	$ (36.66)
Loss from discontinued operations, basic calculation		(0.67)		(0.28)
Deemed dividend and accretion of a discount, basic calculation	(2.53)	(37.62)	(2.84)	(47.46)
Net loss attributable to common stockholders, basic calculation	(3.31)	(49.48)	(5.68)	(84.40)
Loss from continuing operations, diluted calculation	(1.46)	(12.06)	(3.58)	(39.01)
Loss from discontinued operations, diluted calculation		(0.42)		(0.28)
Deemed dividend and accretion of a discount, diluted calculation	(2.53)	(23.33)	(2.84)	(47.46)
Net loss attributable to common stockholders, diluted calculation	$ (3.99)	$ (35.81)	$ (6.42)	$ (86.75)

XML 44 R34.htm IDEA: XBRL DOCUMENT

Inventories (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventories, current	$ 85	$ 52
Inventories, non - current	$ 600

XML 45 R35.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Components of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 596	$ 624
Intermediate goods	9
WIP	76	47
Finished goods		5
Inventory	$ 596	$ 624

XML 46 R36.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Intangible Assets (Details) - Trademarks [Member] - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 50	$ 50
Less accumulated amortization	(6)	(4)
Intangible assets, net	$ 44	$ 46

XML 47 R37.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Weighted average price stock exceeds	$ 3.00
Average daily trading value	$ 400
Warrants [Member]
Weighted average price stock exceeds	$ 0.01
Black-Scholes-Merton Valuation Model [Member]
Derivative liability	$ 900	$ 900
Monte Carlo Simulation Valuation Model [Member]
Derivative liability

XML 48 R38.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 502	$ 504
Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	956	1,566
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Measurements, Recurring [Member] \| Common Stock Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 956	$ 1,566

XML 49 R39.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) - Common Stock Warrants [Member] - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Beginning balance	$ (1,566)	$ (1,357)
Issuances of warrants classified as derivatives		(7,577)
Change in fair value	610	2,020
Exercise of warrants		565
Other, net		(212)
Ending balance	$ (956)	$ (6,561)

XML 50 R40.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) - Common Stock Warrants [Member]	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Black-Scholes-Merton Valuation Model [Member] \| Weighted-Average Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.0223	0.0251
Black-Scholes-Merton Valuation Model [Member] \| Weighted-Average Expected Life [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	4 years 1 month 6 days	10 months 25 days
Black-Scholes-Merton Valuation Model [Member] \| Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.00	0.00
Black-Scholes-Merton Valuation Model [Member] \| Weighted-Average Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.68	1.57
Monte Carlo Simulation Valuation Model [Member] \| Weighted-Average Risk-Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.0172	0.0246
Monte Carlo Simulation Valuation Model [Member] \| Weighted-Average Expected Life [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	2 years 4 months 24 days	3 years 1 month 6 days
Monte Carlo Simulation Valuation Model [Member] \| Expected Dividend Yield [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.00	0.00
Monte Carlo Simulation Valuation Model [Member] \| Weighted-Average Expected Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentages	0.64	0.68

XML 51 R41.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Payroll and related expense	$ 413	$ 388
Resterilization and repackaging costs	344	344
Other	56	106
Total accrued liabilities	$ 813	$ 838

XML 52 R42.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands					6 Months Ended
	May 14, 2018	Jan. 03, 2018	Jul. 28, 2017	Jun. 30, 2014	Jun. 30, 2019	Jun. 30, 2018	Oct. 31, 2018	Jan. 31, 2018
Percentage of loan bear interest rate							10.00%
Total payoff amount						$ 2,282
Debt maturity date					Oct. 01, 2021
North Stadium Investments, LLC [Member]
Debt principal amount			$ 2,500
Warrant to purchase shares of common stock			1,834
Warrant exercise price per share			$ 151.20
Percentage of loan bear interest rate			10.00%
Debt maturity date			Jul. 28, 2018
Warrant term			5 years
Fair value of warrants			$ 200
Hercules Technology Capital, Inc. [Member] \| Loan and Security Agreement [Member]
Debt principal amount				$ 20,000
Debt maturity date				Jan. 01, 2018
L2 Capital Debt [Member]
Debt principal amount	$ 700							$ 840
Debt purchase price								$ 750
Warrant to purchase shares of common stock								68,257
Warrant exercise price per share								$ 3.31
Percentage of loan bear interest rate								8.00%
Percentage of default interest rate								18.00%
Gross proceeds of convertible preferred stock and warrants	15,000
Total payoff amount	1,100
Interest amount	400
Hercules Term Loan [Member]
Debt principal amount		$ 2,300
Hercules Term Loan [Member] \| Closing Date [Member]
Term loan fee amount				$ 200
Final payment fee for debt				$ 1,700
Hercules Term Loan [Member] \| Senior Secured Convertible Promissory Notes One [Member]
Debt principal amount		1,100
Hercules Term Loan [Member] \| Senior Secured Convertible Promissory Notes Two [Member]
Debt principal amount		$ 2,200
Exchange Notes [Member]
Percentage of loan bear interest rate		15.00%
Debt maturity date		Feb. 03, 2019
MEF I, L.P. and Anson Investments [Member]
Debt principal amount	1,400
Gross proceeds of convertible preferred stock and warrants	15,000
Total payoff amount	1,600
Interest amount	$ 200

XML 53 R43.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			6 Months Ended
	May 14, 2018	Aug. 31, 2018	Jul. 31, 2018	May 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Sep. 07, 2018	Mar. 31, 2018
Gross proceeds of warrants						$ 7,577
Proceeds from public offering	$ 15,000
Preferred stock stated value					$ 0.01		$ 0.01
Common stock state value					0.01		0.01
Conversion price per share	$ 43.50				2.94			$ 14.40
Share price					$ 3.00
Proceeds from issuance of units	$ 6,800					$ 6,754
Preferred stock issuance costs	$ 600
ATM Equity Distribution Agreement [Member]
Sale of stock, shares					144,415
Sale of stock value					$ 400
Payments of stock issuance costs					100
Additional offering value					$ 1,100
July 12, 2018 [Member]
Conversion price per share					$ 19.63
Maximum [Member] \| ATM Equity Distribution Agreement [Member]
Common stock offering price					$ 1,600
Public Offering [Member]
Stock issued price per shares	$ 1,000
Debt conversion, description	The Series B Preferred Stock is convertible into shares of common stock by dividing the stated value of $1,100 by: (i) for the first 40 trading days following the closing of this offering, $43.54 (the "Conversion Price"), (ii) after 40 trading days but prior to the 81st trading day, the lesser of (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the 41st trading day, and (iii) after 80 trading days, the lesser of (a) the Conversion Price and (b) 87.5% of the lowest volume weighted average price for our Common Stock as reported at the close of trading on the market reporting trade prices for the Common Stock during the five trading days prior to the date of the notice of conversion. In the case of (ii)(b) and (iii)(b) above, the share price shall not be less than $2.94 (the "Floor Price"). Each of the Conversion Price and Floor Price is subject to adjustment in certain circumstances.
Conversion price per share	$ 43.54
Debt instrument trading percentage	87.50%
Share price	$ 2.94
August 2018 Warrant Exercise [Member] \| Secondary Offering [Member]
Warrants converted into shares of common stock		8,069
July 2018 Warrant Exercise [Member] \| Public Offering [Member]
Warrants converted into shares of common stock			998
Warrant exercise			998
May 2018 Warrant Exercise (July 2016 Warrants) [Member]
Warrants to purchase of common stock shares				4,861					27,733
Gross proceeds of warrants				$ 300
May 2018 Warrant Exercise (July 2016 Warrants) [Member] \| Minimum [Member]
Warrants exercise price									$ 360
May 2018 Warrant Exercise (July 2016 Warrants) [Member] \| Maximum [Member]
Warrants exercise price									$ 63.75
Convertible Preferred Stock and Warrants [Member]
Proceeds from public offering	$ 15,000
Warrants [Member]
Warrants to purchase of common stock shares	25
Warrants exercise price	$ 48
Warrant term	5 years
Share price					$ 0.01
Number of warrants issued	6,900
Warrants issuance cost	$ 700
Series E Common Stock Purchase Warrant [Member]
Warrant exercise						22,279
Warrants to purchase of common stock shares						27,733
Warrants exercise price						$ 360.00	$ 63.75
Gross proceeds of warrants						$ 1,400
New Warrants [Member]
Warrants exercise price						$ 60.00
Percentage of warrant shares issued for new warrants						100.00%
Series B Convertible Preferred Stock [Member]
Convertible preferred stock shares conversion				4,072	3,337	4,072
Preferred stock stated value	$ 1,100
Common stock state value	$ 1,100
Common Stock [Member]
Convertible preferred stock shares conversion	378,997			102,886	983,528	102,886
Preferred Stock [Member]
Convertible preferred stock shares conversion	15,000
July Through December of 2018 [Member] \| Series B Convertible Preferred Stock [Member]
Convertible preferred stock shares conversion					10,926
July Through December of 2018 [Member] \| Common Stock [Member]
Convertible preferred stock shares conversion					569,966

XML 54 R44.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2019 USD ($) $ / shares shares
Share-based Payment Arrangement [Abstract]
Options, Outstanding at beginning of period \| shares	377
Options, Granted \| shares
Options, Exercised \| shares
Options, Forfeited \| shares
Options, Expired \| shares
Options, Outstanding at end of period \| shares	377
Options, Exercisable at end of period \| shares	371
Options, Expected to vest at end of period \| shares	377
Weighted Average Exercise Price, Outstanding at beginning of period \| $ / shares	$ 7,653
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Forfeited \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Outstanding at end of period \| $ / shares	7,653
Weighted Average Exercise Price, Exercisable at end of period \| $ / shares	7,551
Weighted Average Exercise Price, Expected to vest at end of period \| $ / shares	$ 7,653
Weighted Average Remaining Contractual Terms (Years), Outstanding at beginning	6 years
Weighted Average Remaining Contractual Terms (Years), Outstanding at ending	5 years 9 months 18 days
Weighted Average Remaining Contractual Terms (Years), Exercisable	6 years 3 months 19 days
Weighted Average Remaining Contractual Terms (years), Expected to vest	5 years 6 months
Intrinsic Value, Outstanding at beginning of period \| $
Intrinsic Value, Outstanding at end of period \| $
Intrinsic Value, Exercisable at end of period \| $
Intrinsic Value, Expected to vest at end of period \| $

XML 55 R45.htm IDEA: XBRL DOCUMENT

Note Receivable (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
Note Receivable (Details Narrative) - USD ($)	Oct. 02, 2018	Oct. 31, 2018	Jun. 30, 2019
Non interest note receivable	$ 6,000,000
Debt description	The 36-month term of the note receivable requires 18 payments of $138,889 followed by 18 payments of $194,444, with maturing of the note receivable on October 1, 2021.
Payments of notes receivable	$ 138,889		$ 194,444
Maturity date of note receivable			Oct. 01, 2021
Debt instrument imputed interest percentage		10.00%
Imputed interest		$ 915,725
Imputed interest, description		The note receivable includes an imputed interest rate of 10%, which totaled $915,725 as of October 31, 2018, and has a 36-month amortization. As of June 30, 2019, the net carrying value of the note receivable was approximately $4.3 million.
Discontinued Operations, Spine Business [Member]
Non interest note receivable			$ 4,300,000

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 56 R46.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Details Narrative) - USD ($) $ in Thousands		3 Months Ended
	Oct. 02, 2018	Dec. 31, 2018
Asset Purchase Agreement [Member]
Total consideration	$ 8,500
Agreement extension description	This agreement extends for a total of 24 months, ending on September 30, 2020.
Asset Purchase Agreement [Member] \| Related Party Note Payable [Member]
Total consideration	$ 2,500
Sterilization and repackaging cost	500
Asset Purchase Agreement [Member] \| Interest Note Receivable [Member]
Total consideration	$ 6,000
Retail Spine Business [Member]
Gain on the sale of business		$ 1,400

XML 57 R47.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Schedule of Discontinued Operations (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2018 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Product revenue	$ 4,330
Costs of revenue	1,045
Gross profit	3,285
Research and development	717
General and administrative	348
Sales and marketing	2,264
Total operating expenses	3,329
Loss from discontinued operations	$ (44)

XML 58 R48.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) $ in Thousands		3 Months Ended	6 Months Ended
Leases (Details Narrative) $ in Thousands	Jun. 07, 2019 ft²	Jun. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jan. 02, 2019 USD ($)	Dec. 31, 2018 USD ($)
Leases [Abstract]
Lease expired, description			The Company leases office, warehouse and manufacturing space under a single operating lease, which lease originally expired during 2019
Lease extended period, description	On June 7, 2019, the lease was amended to extend the rental period through 2024		The amended lease has two five-year extension options.
Area of lease \| ft²	54,428
Reduction of lease area \| ft²	29,534
Operating lease right-of-use asset		$ 2,535	$ 2,535		$ 659
Operating lease liability		$ 2,637	2,637		$ 946
Non-cash lease expense			$ 171	$ (99)
Operating lease weighted-average discount rate		6.50%	6.50%
Loss on amendment lease		$ 120

XML 59 R49.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Operating Lease Future Minimum Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 02, 2019	Dec. 31, 2018
Leases [Abstract]
2019	$ 490
2020	494
2021	509
2022	525
2023	540
Thereafter	556
Total future minimum lease payments	3,114
Less amounts representing interests	(477)
Present value of lease liability	2,637	$ 946
Current-portion of operating lease liability	587		$ 169
Long-term portion operating lease liability	$ 2,050

XML 60 R50.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative)	Jul. 26, 2019
Subsequent Event [Member]
Reverse stock split, description	1 for 30 reverse stock split

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

^N5R") <$B2' LDQ!,DQ LEQ"Y+C#B3' M/4@./D )@B(J1R&5HYC*45#E**IR%%8YBJL&UL4$L! A0#% @ S$.3Q#7 MD3R5 @ "PH !@ ( !^ @ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0#% @ S$.3W*A0'@3!@ TB$ !@ M ( !E!( 'AL+W=O&PO=V]R:W-H965T&UL4$L! M A0#% @ S$.3U/_6 D @ B@4 !@ ( !,20 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ S$.3SQQ ME3ZU 0 T , !D ( !.BH 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ S$.3^V+&PO M=V]R:W-H965T&UL4$L! A0#% @ S$.3\->0%>T 0 T@, !D ( ! MO#4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ S$.3RAZ$.>T 0 T@, !D ( !?3L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ S$.3TG]O&BW 0 T@, !D M ( !7$< 'AL+W=O&PO=V]R M:W-H965TCOMP$ -(# M 9 " 6-+ !X;"]W;W)K&UL M4$L! A0#% @ S$.3]3VC!6X 0 T@, !D ( !44T M 'AL+W=O M8+4! #2 P &0 @ % 3P >&PO=V]R:W-H965T&UL4$L! A0#% @ M S$.3Q5JY'D9! *10 !D ( !&5, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ S$.3_4^(4L @ !P8 !D M ( !:&0 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ S$.3ZJ.+]G6 @ ,PP !D ( !&PO=V]R:W-H965T&UL4$L! A0#% @ S$. M3S37V"V(!0 (A\ !D ( !Y70 'AL+W=O@ >&PO=V]R:W-H965T&UL4$L! A0#% @ S$.3UWONG81 @ = 8 M !D ( !-H 'AL+W=O&PO=V]R:W-H965T6$ !X;"]W;W)K&UL4$L! A0#% @ S$.3V!"S!MP @ <0@ !D M ( !HX< 'AL+W=O&PO=V]R:W-H965T M M : " 37N !X;"]? 3 " 4?P K !;0V]N=&5N=%]4>7!E&UL4$L%!@ [ #L #Q #_R $! end XML 62 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 144 385 1 false 55 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://ww.sintx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://ww.sintx.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://ww.sintx.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://ww.sintx.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://ww.sintx.com/role/StatementsOfStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://ww.sintx.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://ww.sintx.com/role/StatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 7 false false R8.htm 00000008 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://ww.sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Basic and Diluted Net Loss Per Common Share Sheet http://ww.sintx.com/role/BasicAndDilutedNetLossPerCommonShare Basic and Diluted Net Loss Per Common Share Notes 9 false false R10.htm 00000010 - Disclosure - Inventories Sheet http://ww.sintx.com/role/Inventories Inventories Notes 10 false false R11.htm 00000011 - Disclosure - Intangible Assets Sheet http://ww.sintx.com/role/IntangibleAssets Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value Measurements Sheet http://ww.sintx.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 00000013 - Disclosure - Accrued Liabilities Sheet http://ww.sintx.com/role/AccruedLiabilities Accrued Liabilities Notes 13 false false R14.htm 00000014 - Disclosure - Debt Sheet http://ww.sintx.com/role/Debt Debt Notes 14 false false R15.htm 00000015 - Disclosure - Equity Sheet http://ww.sintx.com/role/Equity Equity Notes 15 false false R16.htm 00000016 - Disclosure - Stock-Based Compensation Sheet http://ww.sintx.com/role/Stock-basedCompensation Stock-Based Compensation Notes 16 false false R17.htm 00000017 - Disclosure - Commitments and Contingencies Sheet http://ww.sintx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 00000018 - Disclosure - Note Receivable Sheet http://ww.sintx.com/role/NoteReceivable Note Receivable Notes 18 false false R19.htm 00000019 - Disclosure - Discontinued Operations Sheet http://ww.sintx.com/role/DiscontinuedOperations Discontinued Operations Notes 19 false false R20.htm 00000020 - Disclosure - Leases Sheet http://ww.sintx.com/role/Leases Leases Notes 20 false false R21.htm 00000021 - Disclosure - Subsequent Events Sheet http://ww.sintx.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 00000022 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://ww.sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://ww.sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Basic and Diluted Net Loss Per Common Share (Tables) Sheet http://ww.sintx.com/role/BasicAndDilutedNetLossPerCommonShareTables Basic and Diluted Net Loss Per Common Share (Tables) Tables http://ww.sintx.com/role/BasicAndDilutedNetLossPerCommonShare 23 false false R24.htm 00000024 - Disclosure - Inventories (Tables) Sheet http://ww.sintx.com/role/InventoriesTables Inventories (Tables) Tables http://ww.sintx.com/role/Inventories 24 false false R25.htm 00000025 - Disclosure - Intangible Assets (Tables) Sheet http://ww.sintx.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://ww.sintx.com/role/IntangibleAssets 25 false false R26.htm 00000026 - Disclosure - Fair Value Measurements (Tables) Sheet http://ww.sintx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://ww.sintx.com/role/FairValueMeasurements 26 false false R27.htm 00000027 - Disclosure - Accrued Liabilities (Tables) Sheet http://ww.sintx.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://ww.sintx.com/role/AccruedLiabilities 27 false false R28.htm 00000028 - Disclosure - Stock-Based Compensation (Tables) Sheet http://ww.sintx.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://ww.sintx.com/role/Stock-basedCompensation 28 false false R29.htm 00000029 - Disclosure - Discontinued Operations (Tables) Sheet http://ww.sintx.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://ww.sintx.com/role/DiscontinuedOperations 29 false false R30.htm 00000030 - Disclosure - Leases (Tables) Sheet http://ww.sintx.com/role/LeasesTables Leases (Tables) Tables http://ww.sintx.com/role/Leases 30 false false R31.htm 00000031 - Disclosure - Organization and Summary of Significant Accounting Policies (Details Narrative) Sheet http://ww.sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative Organization and Summary of Significant Accounting Policies (Details Narrative) Details http://ww.sintx.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 31 false false R32.htm 00000032 - Disclosure - Basic and Diluted Net Loss Per Common Share (Details Narrative) Sheet http://ww.sintx.com/role/BasicAndDilutedNetLossPerCommonShareDetailsNarrative Basic and Diluted Net Loss Per Common Share (Details Narrative) Details http://ww.sintx.com/role/BasicAndDilutedNetLossPerCommonShareTables 32 false false R33.htm 00000033 - Disclosure - Basic and Diluted Net Loss Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) Sheet http://ww.sintx.com/role/BasicAndDilutedNetLossPerCommonShare-ScheduleOfBasicAndDilutedLossPerShareDetails Basic and Diluted Net Loss Per Common Share - Schedule of Basic and Diluted Loss Per Share (Details) Details 33 false false R34.htm 00000034 - Disclosure - Inventories (Details Narrative) Sheet http://ww.sintx.com/role/InventoriesDetailsNarrative Inventories (Details Narrative) Details http://ww.sintx.com/role/InventoriesTables 34 false false R35.htm 00000035 - Disclosure - Inventories - Schedule of Components of Inventory (Details) Sheet http://ww.sintx.com/role/Inventories-ScheduleOfComponentsOfInventoryDetails Inventories - Schedule of Components of Inventory (Details) Details 35 false false R36.htm 00000036 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) Sheet http://ww.sintx.com/role/IntangibleAssets-ScheduleOfIntangibleAssetsDetails Intangible Assets - Schedule of Intangible Assets (Details) Details 36 false false R37.htm 00000037 - Disclosure - Fair Value Measurements (Details Narrative) Sheet http://ww.sintx.com/role/FairValueMeasurementsDetailsNarrative Fair Value Measurements (Details Narrative) Details http://ww.sintx.com/role/FairValueMeasurementsTables 37 false false R38.htm 00000038 - Disclosure - Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) Sheet http://ww.sintx.com/role/FairValueMeasurements-ScheduleOfFinancialLiabilitiesMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails Fair Value Measurements - Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis by Level within Fair Value Hierarchy (Details) Details 38 false false R39.htm 00000039 - Disclosure - Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) Sheet http://ww.sintx.com/role/FairValueMeasurements-ScheduleOfFairValueMeasurementHierarchyOfDerivativeLiabilityDetails Fair Value Measurements - Schedule of Fair Value Measurement Hierarchy of Derivative Liability (Details) Details 39 false false R40.htm 00000040 - Disclosure - Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) Sheet http://ww.sintx.com/role/FairValueMeasurements-ScheduleOfAssumptionsUsedInEstimatingFairValueDetails Fair Value Measurements - Schedule of Assumptions Used in Estimating Fair Value (Details) Details 40 false false R41.htm 00000041 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details) Sheet http://ww.sintx.com/role/AccruedLiabilities-ScheduleOfAccruedLiabilitiesDetails Accrued Liabilities - Schedule of Accrued Liabilities (Details) Details 41 false false R42.htm 00000042 - Disclosure - Debt (Details Narrative) Sheet http://ww.sintx.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://ww.sintx.com/role/Debt 42 false false R43.htm 00000043 - Disclosure - Equity (Details Narrative) Sheet http://ww.sintx.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://ww.sintx.com/role/Equity 43 false false R44.htm 00000044 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details) Sheet http://ww.sintx.com/role/Stock-basedCompensation-SummaryOfStockOptionActivityDetails Stock-Based Compensation - Summary of Stock Option Activity (Details) Details 44 false false R45.htm 00000045 - Disclosure - Note Receivable (Details Narrative) Sheet http://ww.sintx.com/role/NoteReceivableDetailsNarrative Note Receivable (Details Narrative) Details http://ww.sintx.com/role/NoteReceivable 45 false false R46.htm 00000046 - Disclosure - Discontinued Operations (Details Narrative) Sheet http://ww.sintx.com/role/DiscontinuedOperationsDetailsNarrative Discontinued Operations (Details Narrative) Details http://ww.sintx.com/role/DiscontinuedOperationsTables 46 false false R47.htm 00000047 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Details) Sheet http://ww.sintx.com/role/DiscontinuedOperations-ScheduleOfDiscontinuedOperationsDetails Discontinued Operations - Schedule of Discontinued Operations (Details) Details 47 false false R48.htm 00000048 - Disclosure - Leases (Details Narrative) Sheet http://ww.sintx.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://ww.sintx.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - Leases - Schedule of Operating Lease Future Minimum Payments (Details) Sheet http://ww.sintx.com/role/Leases-ScheduleOfOperatingLeaseFutureMinimumPaymentsDetails Leases - Schedule of Operating Lease Future Minimum Payments (Details) Details 49 false false R50.htm 00000050 - Disclosure - Subsequent Events (Details Narrative) Sheet http://ww.sintx.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://ww.sintx.com/role/SubsequentEvents 50 false false All Reports Book All Reports sint-20190630.xml sint-20190630.xsd sint-20190630_cal.xml sint-20190630_def.xml sint-20190630_lab.xml sint-20190630_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 true true ZIP 66 0001493152-19-012287-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-012287-xbrl.zip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